PROTOCOL

TITLE
An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia¹

PROTOCOL NUMBER
ACE-WM-001

STUDY DRUG
ACP-196 (acalabrutinib)

IND NUMBER
118717

EUDRACT NUMBER
2014-003212-36

SPONSOR MEDICAL MONITOR

SPONSOR
Acerta Pharma BV
Kloosterstraat 9
5349 AB Oss
The Netherlands

PROTOCOL DATE
Version 0.0 – 12 May 2014

AMENDMENT 1 DATE
Version 1.0 – 19 September 2014 (all sites)

AMENDMENT 2 DATE
Version 2.0 – 17 November 2014 (Netherlands only)
Version 2.1 – 20 November 2014 (US only)
Version 3.0 – 05 January 2015 (UK/US only)

AMENDMENT 3 DATE
Version 3.1 – 13 March 2015 (all sites)

AMENDMENT 4 DATE
Version 4.0 – 14 January 2016 (all sites)
Version 4.1 – 01 April 2016 (Italy only)

AMENDMENT 5 DATE
Version 5.0 – 23 June 2016 (all sites)
Version 5.1 – 04 October 2016 (Italy only)

AMENDMENT 6 DATE
Version 6.0 – 21 December 2016 (all sites)
Version 6.1 – 30 January 2017 (Italy only)

AMENDMENT 7 DATE
Version 7.0 – 26 December 2017 (all sites)
Version 7.1 – 26 December 2017 (Italy only)
Version 7.2 – 06 March 2018 (France only)

AMENDMENT 8 DATE
Version 8.0 – 16 April 2019 (all sites)
Version 8.1 – 16 April 2019 (Italy only)
Version 8.2 – 16 April 2019 (France only)

Confidentiality Statement
This document contains proprietary and confidential information of Acerta Pharma BV that must not be disclosed to anyone other than the recipient study staff and members of the institutional review board/independent ethics committee. This information cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Acerta Pharma BV.

¹ In Italy only, the original protocol title “An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia” remains in effect.
PROTOCOL APPROVAL

I have carefully read Protocol ACE-WM-001 entitled “An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia.” I agree to conduct this study as outlined herein and in compliance with Good Clinical Practices, all applicable regulatory requirements, and with the ethical principles laid down in the Declaration of Helsinki. Furthermore, I understand that the Sponsor, Acerta Pharma, and the Institutional Review Board/Independent Ethics Committee must approve any changes to the protocol in writing before implementation.

I agree not to divulge to anyone, either during or after the termination of the study, any confidential information acquired regarding the investigational product and processes or methods of Acerta Pharma. All data pertaining to this study will be provided to Acerta Pharma. The policy of Acerta Pharma BV requires that any presentation or publication of study data by clinical investigators be reviewed by Acerta Pharma, before release, as specified in the protocol.

Principal Investigator’s Signature

Date

Print Name

2 In Italy only, the original protocol title “An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia” remains in effect.
SUMMARY OF AMENDMENT 8.0

This protocol is being amended to extend the study beyond 48 cycles allowing subjects continuing to receive clinical benefit to continue on treatment until a rollover protocol is available at which time the study will be closed. In addition, the requirement of review of response (overall response rate, duration of overall response, and progression-free survival) by an independent review committee will no longer be conducted.

Substantive changes (noted below) along with clarification edits and typographical corrections were made as part of this amendment.

<table>
<thead>
<tr>
<th>Change</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protocol Title Page</strong></td>
<td></td>
</tr>
<tr>
<td>Updated name and contact information for medical monitor.</td>
<td>Updated sponsor information.</td>
</tr>
<tr>
<td>Listed amendment 8 and dates.</td>
<td>Added new amendment number and date issued.</td>
</tr>
<tr>
<td><strong>Study Synopsis</strong></td>
<td></td>
</tr>
<tr>
<td>Updated to reflect changes made throughout the protocol.</td>
<td>Updated to ensure consistency between the body of the protocol and the synopsis.</td>
</tr>
<tr>
<td><strong>Section 1.2.1 Chemistry</strong></td>
<td></td>
</tr>
<tr>
<td>Updated statement about Calquence® having been approved in the United States and other markets for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.</td>
<td>Updated to be consistent with current regulatory approvals of Calquence.</td>
</tr>
<tr>
<td><strong>Section 1.3.2 Clinical Experience</strong></td>
<td></td>
</tr>
<tr>
<td>Updated the number of subjects with who have received acalabrutinib in clinical studies.</td>
<td>Updated data to be consistent with most current Investigator Brochure.</td>
</tr>
<tr>
<td>Updated the subject population of Study ACE-CL-001 to be subjects with chronic lymphocytic leukemia (CLL), including subjects with relapsed/refractory CLL, treatment-naive subjects, ibrutinib-intolerant subjects, and subjects with Richter's syndrome or prolymphocytic leukemia transformation.</td>
<td>Updated for clarity.</td>
</tr>
<tr>
<td>Updated the number of subjects in Study ACE-CL-001 and the preliminary efficacy data for them.</td>
<td>Updated data to be consistent with most current Investigator Brochure.</td>
</tr>
<tr>
<td><strong>Section 1.4 Secondary Objectives</strong></td>
<td></td>
</tr>
<tr>
<td>Deleted the description of Study ACE-CL-001.</td>
<td>Deleted text because information is in the previous section.</td>
</tr>
<tr>
<td>Deleted response data for Study ACE-CL-001.</td>
<td>Changed to make text more general.</td>
</tr>
<tr>
<td>Change</td>
<td>Rationale</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Section 2.2 Secondary Objectives</strong></td>
<td>Updated because a review/confirmation by an independent review committee is no longer prescribed.</td>
</tr>
<tr>
<td>Removed text from objectives referring to the review by an independent review committee.</td>
<td></td>
</tr>
<tr>
<td><strong>Section 3.1 Description of Study</strong></td>
<td>Updated because a review/confirmation by an independent review committee is no longer prescribed.</td>
</tr>
<tr>
<td>Removed specific assessment times for safety parameters and added a link to Appendix 4 for the information.</td>
<td></td>
</tr>
<tr>
<td>Added text that assessments for efficacy will be completed throughout the study as per Appendix 4.</td>
<td></td>
</tr>
<tr>
<td>Deleted text stating that an independent review committee will be used to confirm overall response rate, duration of response, and progression-free survival.</td>
<td>Updated for clarity.</td>
</tr>
<tr>
<td>Deleted the word “independent” describing the interim analysis.</td>
<td></td>
</tr>
<tr>
<td>Updated text to define end of study as the last subject’s last visit and that the sponsor may terminate the study at any time. Added that the study duration is expected to be approximately 6 years from enrollment of the last subject.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Clarified that subjects who are deriving clinical benefit from acalabrutinib treatment may be eligible to enroll in a separate rollover study when it is available.</td>
<td>Added to provide clarification that subjects could switch to a separate rollover study before the end of study.</td>
</tr>
<tr>
<td><strong>Section 3.2.2 Secondary Endpoints</strong></td>
<td>Updated because a review/confirmation by an independent review committee is no longer prescribed.</td>
</tr>
<tr>
<td>Removed text from objectives referring to the review by an independent review committee.</td>
<td></td>
</tr>
<tr>
<td><strong>Section 3.7.7 Reproductive Toxicity</strong></td>
<td>Updated information to be consistent with most current Investigator Brochure and with other protocols across the program.</td>
</tr>
<tr>
<td>Updated the definition of highly effective methods of contraception.</td>
<td></td>
</tr>
<tr>
<td><strong>Section 4.1.13 Serum Chemistry</strong></td>
<td>Added an appendix for Hy’s law information to be consistent with protocols across the program.</td>
</tr>
<tr>
<td>Added a reference to Appendix 5 for actions required in cases of increases in liver biochemistry and evaluation of Hy’s law.</td>
<td></td>
</tr>
<tr>
<td><strong>Section 4.1.21 Extramedullary Disease Assessment</strong></td>
<td>Changed from every 3 cycles to every 6 cycles to reflect current standard of care.</td>
</tr>
<tr>
<td>Changed frequency of radiologic assessments for extramedullary disease from every 3 cycles to every 6 cycles after Cycle 6.</td>
<td>Updated because a review/confirmation by an independent review committee is no longer prescribed.</td>
</tr>
<tr>
<td>Removed text referring to the review by a central imaging vendor being used to provide independent radiologic assessments for the purposes of confirming overall response rate.</td>
<td></td>
</tr>
<tr>
<td>Change</td>
<td>Rationale</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Section 4.4 Follow-Up for Progression and Survival</strong></td>
<td>Changed text to indicate that during the discontinuation follow-up period, serum IgM and physical examinations will be collected every 6 months. Changed from every month to every 6 months was made to reflect current standard of care.</td>
</tr>
<tr>
<td><strong>Section 5.5.3 Analysis of Efficacy Parameters</strong></td>
<td>Updated because a review/confirmation by an independent review committee is no longer prescribed.</td>
</tr>
<tr>
<td><strong>Section 5.7 Primary and Final Analysis</strong></td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td><strong>Section 6.1.3 Adverse Events of Special Interest</strong></td>
<td>Added information to be consistent with protocols across the program.</td>
</tr>
<tr>
<td><strong>Section 6.1.5 Adverse Drug Reactions</strong></td>
<td>Added section for additional clarification of reporting AEs and SAEs.</td>
</tr>
<tr>
<td><strong>Section 6.2.4 Expedited Reporting Requirements for Serious Adverse Events and Adverse Events of Special Interest</strong></td>
<td>Added for consistency with Section 6.1.3 and to be consistent with protocols across the program.</td>
</tr>
<tr>
<td><strong>Appendix 4 Schedule of Assessments</strong></td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Updated column for Cycle 27+ to be Cycles 27 to 48</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Added a column for Cycles 48+ and indicated the following assessments would be made for these cycles: physical examination/vital signs/weight, Eastern Cooperative Oncology Group status, urine or serum pregnancy test, hematology, serum chemistry, serum Ig and M protein, hepatitis B virus polymerase chain reaction, bone marrow (aspirate and biopsy), radiologic assessment for extramedullary sites, acalabrutinib dispensed, study drug compliance, response assessment, concomitant medications, and patient-reported outcomes. Updated footnotes to define end of study as the last subject's last visit and that subjects who are deriving clinical benefit from acalabrutinib may continue on study until a rollover protocol is available.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Change</td>
<td>Rationale</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Updated footnotes to indicate physical examination and weight assessments will be made every 3 cycles through Cycle 48, then every 6 cycles thereafter.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Updated footnotes to indicate vital signs assessments will be made every 3 cycles through Cycle 48, then every 6 cycles thereafter.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Updated footnotes to indicate electrocardiogram assessments will be made every 3 cycles through Cycle 48, then every 6 cycles thereafter.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Updated footnotes to indicate pregnancy testing, in general, will be made every 3 cycles through Cycle 48, then every 6 cycles thereafter.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Updated footnotes to indicate hematology assessments will be made every 3 cycles through Cycle 48, then every 6 cycles thereafter.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Updated footnotes to indicate serum chemistry assessments will be made every 3 cycles through Cycle 48, then every 6 cycles thereafter.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Updated footnotes to indicate T/B/natural killer cell count assessments during Cycle 6 through Cycle 24, would only be done at end of Cycle 6, 12, 18, and 24, and that during Cycle 27 through Cycle 48, assessments would be done every 6 cycles starting at Cycle 27. It was also noted that assessments after Cycle 48 are not required.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Updated footnotes to indicate serum immunoglobulin and serum M protein will be done every 3 cycles starting at Cycle 6 and going through Cycle 48, then every 6 cycles thereafter.</td>
<td>Updated because study was extended 2 years.</td>
</tr>
<tr>
<td>Updated footnotes to indicate patient-reported outcome assessments after Cycle 6 will be done every 6 cycles until documentation of progressive disease or use of alternative anticancer therapy.</td>
<td>Changed from every 3 cycles to every 6 cycles was made to reflect current standard of care.</td>
</tr>
<tr>
<td>Updated footnotes to indicate that subjects who are hepatitis B core antibody positive (or have a known history of hepatitis B virus infection) should be monitored monthly with a quantitative polymerase chain reaction test for hepatitis B virus DNA, and the assessments will be made monthly from Cycle 6 to Cycle 48 or early discontinuation, and then every 3 months thereafter. Also, assessments were changed from monthly to every 3 months during the discontinuation follow-up period and the long-term follow-up period.</td>
<td>Changed from monthly to every 3 months because subjects negative for hepatitis B surface antigen, positive for hepatitis B core antibodies, and negative for polymerase chain reaction results are considered low risk for reactivation and can be monitored quarterly.</td>
</tr>
<tr>
<td>Change</td>
<td>Rationale</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Appendix 5</strong> Actions Required in Cases of Increases in Liver Biochemistry and Evaluation of Hy’s Law</td>
<td>Added an appendix for actions required in cases of increases in liver biochemistry and evaluation of Hy’s law.</td>
</tr>
</tbody>
</table>
1.0 BACKGROUND INFORMATION ......................................................... 25
  1.1 Role of BTK in Lymphoid Cancers .................................................... 25
  1.2 Preclinical Studies ............................................................................. 26
    1.2.1 Chemistry ................................................................................... 26
    1.2.2 Mechanism of Action of Acalabrutinib ....................................... 26
    1.2.3 Dog Lymphoma Study ................................................................. 26
    1.2.4 Acalabrutinib and Antibody-dependent Cell-mediated Cytotoxicity
    ........................................................................................................... 27
    1.2.5 Acalabrutinib and Thrombus Formation ..................................... 28
    1.2.6 Safety Pharmacology ................................................................. 29
    1.2.7 Drug-Drug Interaction Potential ................................................. 30
    1.2.8 In Vivo General Toxicology ........................................................ 31
  1.3 Clinical Studies ................................................................................ 31
    1.3.1 Pharmacokinetics and Pharmacodynamics of Acalabrutinib in
    Clinical Pharmacology Studies .......................................................... 31
    1.3.2 Clinical Experience ................................................................... 32
  1.4 Benefit/Risk ...................................................................................... 33
  1.5 Summary and Conclusions ............................................................... 33
2.0 STUDY OBJECTIVES .............................................................................. 33
  2.1 Primary Objective ................................................................. 33
  2.2 Secondary Objectives ................................................................. 33
  2.3 Exploratory Objective ................................................................. 33
3.0 STUDY DESIGN ...................................................................................... 34
  3.1 Description of Study ........................................................................ 34
  3.2 Study Endpoints and Parameters ...................................................... 35
    3.2.1 Co-Primary Endpoints ............................................................... 35
    3.2.2 Secondary Endpoints ................................................................. 35
3.2.3 Exploratory Endpoints .......................................................... 36
3.2.4 Safety Parameters .................................................................. 36
3.2.5 Pharmacokinetic and Pharmacodynamic Parameters .......... 36
3.3 Rationale for Study Design and Dosing Regimen ..................... 36
3.4 Selection of Study Population .................................................. 37
  3.4.1 Inclusion Criteria ............................................................... 37
  3.4.2 Exclusion Criteria .............................................................. 37
  3.4.3 Replacement of Subjects .................................................... 38
  3.4.4 Enrollment Procedures ....................................................... 39
3.5 Study Drug .............................................................................. 39
  3.5.1 Premedications ................................................................. 39
  3.5.2 Formulation, Packaging, and Storage ................................. 39
  3.5.3 Administration of Study Drug ............................................ 40
  3.5.4 Assuring Subject Compliance ............................................ 40
  3.5.5 Dose Delays ..................................................................... 40
  3.5.6 Dose Modification and Discontinuation ............................. 41
3.6 Concomitant Therapy .............................................................. 42
  3.6.1 Permitted Concomitant Therapy ........................................ 42
  3.6.2 Guideline for Use of CYP Inhibiting/Inducing Drugs .......... 42
  3.6.3 Guideline for Use of Drugs that Affect Gastric pH ............... 42
  3.6.4 Prohibited Concomitant Therapy ....................................... 43
3.7 Risks Associated with Acalabrutinib Treatment ....................... 43
  3.7.1 Hemorrhage .................................................................... 43
  3.7.2 Infections ......................................................................... 43
  3.7.3 Cytopenia ........................................................................ 44
  3.7.4 Second Primary Malignancies ......................................... 44
  3.7.5 Atrial Fibrillation ............................................................... 45
  3.7.6 Dietary Restrictions .......................................................... 45
  3.7.7 Reproductive Toxicity ......................................................... 45
  3.7.8 Overdose Instructions ....................................................... 47
3.8 Withdrawal of Subjects from Study Treatment ....................... 47
3.9 Reasons for Study Exit ............................................................ 48
3.10 Data and Safety Monitoring .................................................... 48
4.0 STUDY ACTIVITIES AND ASSESSMENTS ............................... 48
4.1 Description of Procedures ....................................................... 49
  4.1.1 Informed Consent ............................................................. 49
  4.1.2 Medical History ............................................................... 49
  4.1.3 Adverse Events ............................................................... 49
  4.1.4 Concomitant Medications and Therapy ............................. 49
4.1.5 Confirmation of Eligibility ............................................................ 49
4.1.6 ECOG Performance Status .......................................................... 49
4.1.7 Physical Examination, Vital Signs, Height & Weight ..................... 50
4.1.8 Patient-Reported Outcomes ....................................................... 50
4.1.9 Bone Marrow Aspirate and Biopsy ............................................. 50
4.1.10 Electrocardiogram ..................................................................... 50
4.1.11 Urine or Serum Pregnancy Test ............................................... 51
4.1.12 Hematology ................................................................................ 51
4.1.13 Serum Chemistry ........................................................................ 51
4.1.14 Urinalysis .................................................................................... 51
4.1.15 T/B/NK Cell Count ...................................................................... 51
4.1.16 Serum Immunoglobulin and Serum M protein ............................. 51
4.1.17 HBV PCR Testing ....................................................................... 51
4.1.18 Pharmacodynamics .................................................................... 52
4.1.19 Pharmacokinetics ....................................................................... 52
4.1.20 Molecular Testing ....................................................................... 52
4.1.21 Extramedullary Disease Assessment ......................................... 52
4.1.22 Study Drug Accountability ......................................................... 53
4.1.23 Routine Clinical Assessments .................................................... 54
4.2 Investigator’s Assessment of Response to Treatment ......................... 54
4.3 Treatment Termination and Safety Follow-Up Visits ............................ 56
4.4 Follow-Up for Progression and Survival ........................................... 57
4.5 Missed Evaluations .......................................................................... 57
5.0 STATISTICAL METHODS OF ANALYSIS ....................................... 57
5.1 General Considerations .................................................................... 57
5.2 Sample Size Considerations .............................................................. 58
5.3 Definition of Analysis Populations .................................................... 58
5.4 Missing Data Handling ...................................................................... 58
5.5 Endpoint Data Analysis .................................................................... 58
5.5.1 Safety Analysis ........................................................................... 58
5.5.2 Demographics and Baseline Characteristics .................................. 59
5.5.3 Analysis of Efficacy Parameters .................................................. 59
5.5.4 Analysis of Pharmacokinetic/Pharmacodynamic Parameters .... 60
5.5.5 Explorative or Correlative Analyses ............................................ 61
5.5.6 Patient-Reported Outcome ......................................................... 61
5.6 Interim Analysis ............................................................................... 61
5.7 Primary and Final Analysis ............................................................... 62
6.0 ASSESSMENT OF SAFETY ............................................................. 62
6.1 Definitions ....................................................................................... 62
6.1.1 Adverse Events .......................................................................... 62
6.1.2 Serious Adverse Event............................................................... 64
6.1.3 Adverse Events of Special Interest ............................................. 64
6.1.4 Severity ...................................................................................... 65
6.1.5 Adverse Drug Reactions ............................................................ 65

6.2 Documenting and Reporting of Adverse and Serious Adverse Events .... 65
  6.2.1 Adverse Event Reporting Period ................................................ 65
  6.2.2 Assessment of Adverse Events .................................................. 66
  6.2.3 Pregnancy ................................................................................ 66
  6.2.4 Expedited Reporting Requirements for Serious Adverse Events and Adverse Events of Special Interest ......................... 67
  6.2.5 Type and Duration of Follow-up of Subjects After Adverse Events ....................................................................................... 68

7.0 STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS ...... 68
  7.1 Regulatory and Ethical Compliance ......................................................... 69
  7.2 Institutional Review Board and Independent Ethics Committee ............... 69
  7.3 Informed Consent and Protected Subject Health Information Authorization .......................................................................................... 69
  7.4 Subject Screening Log ............................................................................. 70
  7.5 Case Report Forms ............................................................................... 70
  7.6 Study Monitoring Requirements ............................................................... 70
  7.7 Investigational Study Drug Accountability ................................................ 71
  7.8 Record Retention ..................................................................................... 72
  7.9 Protocol Amendments .............................................................................. 72
  7.10 Publication of Study Results .................................................................... 73
  7.11 Clinical Study Insurance ......................................................................... 73
  7.12 General Investigator Responsibilities ....................................................... 73

8.0 REFERENCES ........................................................................................ 74

9.0 APPENDICES ......................................................................................... 76

IN–TEXT TABLES
  Table 1. Drug Discontinuation Actions for Acalabrutinib ................................................41
  Table 2. Pharmacokinetic Sample Schedule ................................................................. 52
  Table 3. Response Assessment Criteria for Waldenström Macroglobulinemia (Owen 2013) .....................................................................................................................55
  Table 4. Progressive Disease Criteria for Waldenström Macroglobulinemia (Owen 2013) .....................................................................................................................55
  Table 5. Response Assessment for Waldenström Macroglobulinemia (Modified 3rd IWWM Workshop Criteria; Kimby 2006) .....................................................................................................................56
  Table 6. Progressive Disease Criteria for Waldenström Macroglobulinemia (Modified 3rd IWWM Workshop Criteria; Kimby 2006) .....................................................................................................................56
IN-TEXT FIGURES

Figure 1. NK Cell Natural Cytotoxicity .................................................................28
Figure 2. In Vivo Thrombus Formation ...............................................................29

LIST OF APPENDICES

Appendix 1. Performance Status Scores .............................................................76
Appendix 2. Adverse Event Assessment of Causality ......................................77
Appendix 3. Known Strong In Vivo Inhibitors and Inducers of CYP3A ............78
Appendix 4. Schedule of Assessments .................................................................79
Appendix 5. Actions Required in Cases of Increases in Liver Biochemistry and Evaluation of Hy’s Law .................................................................83
### ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\lambda_z$</td>
<td>terminal elimination rate constant</td>
</tr>
<tr>
<td>ACP-196</td>
<td>acalabrutinib</td>
</tr>
<tr>
<td>ADCC</td>
<td>antibody-dependent cell-mediated cytotoxicity</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>AESI</td>
<td>adverse event of special interest</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>ANC</td>
<td>absolute neutrophil count</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the curve</td>
</tr>
<tr>
<td>AUC$_{0-12}$</td>
<td>area under the plasma concentration-time curve from 0 to 12 hours, calculated using linear trapezoidal summation</td>
</tr>
<tr>
<td>AUC$_{0-24}$</td>
<td>area under the plasma concentration-time curve from 0 to 24 hours, calculated by doubling the value for AUC$_{0-12}$</td>
</tr>
<tr>
<td>AUC$_{0-\infty}$</td>
<td>area under the plasma concentration-time curve from 0 to infinity, calculated using the formula: $AUC_{0-\infty} = AUC_{0-\text{last}} + \frac{C_T}{\lambda_z}$, where $\lambda_z$ is the apparent terminal elimination rate constant</td>
</tr>
<tr>
<td>AUC$_{0-\text{last}}$</td>
<td>area under the plasma concentration-time curve calculated using linear trapezoidal summation from time 0 to time last, where “last” is the time of the last measurable concentration</td>
</tr>
<tr>
<td>BCL-2</td>
<td>B-cell lymphoma 2</td>
</tr>
<tr>
<td>BCR</td>
<td>B-cell receptor</td>
</tr>
<tr>
<td>BID</td>
<td>twice a day</td>
</tr>
<tr>
<td>BTK</td>
<td>Bruton tyrosine kinase</td>
</tr>
<tr>
<td>CL/F</td>
<td>oral clearance</td>
</tr>
<tr>
<td>CLL</td>
<td>chronic lymphocytic leukemia</td>
</tr>
<tr>
<td>$C_{\text{max}}$</td>
<td>maximum observed plasma concentration</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CRF</td>
<td>case report form</td>
</tr>
<tr>
<td>CSSF</td>
<td>Clinical Supplies Shipping Receipt Form</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of overall response</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>EGFR</td>
<td>epidermal growth factor receptor</td>
</tr>
<tr>
<td>EORTC</td>
<td>European Organisation for Research and Treatment of Cancer</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>hERG</td>
<td>human ether-à-go-go-related gene</td>
</tr>
<tr>
<td>ICF</td>
<td>informed consent form</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>IFE</td>
<td>immunofixation electrophoresis</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>ITK</td>
<td>interleukin-2-inducible T-cell kinase</td>
</tr>
<tr>
<td>IWWM</td>
<td>International Workshops on Waldenström Macroglobulinemia</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MR</td>
<td>minor response</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>NK</td>
<td>natural killer (cells)</td>
</tr>
<tr>
<td>NOAEL</td>
<td>no observable adverse effect level</td>
</tr>
<tr>
<td>OATP</td>
<td>organic-anion-transporting polypeptide</td>
</tr>
<tr>
<td>ORR</td>
<td>overall response rate</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PD</td>
<td>pharmacodynamic</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PI3K</td>
<td>phosphoinositide-3 kinase</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic</td>
</tr>
<tr>
<td>PML</td>
<td>progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PRO</td>
<td>Patient-Reported Outcomes</td>
</tr>
<tr>
<td>QD</td>
<td>once a day</td>
</tr>
<tr>
<td>QTc</td>
<td>corrected QT interval</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>SFU</td>
<td>safety follow-up</td>
</tr>
<tr>
<td>SPEP</td>
<td>serum protein electrophoresis</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reaction (report)</td>
</tr>
<tr>
<td>SYK</td>
<td>spleen tyrosine kinase</td>
</tr>
<tr>
<td>$t_{\text{1/2}}$</td>
<td>terminal elimination half-life</td>
</tr>
<tr>
<td>$T_{\text{max}}$</td>
<td>time to maximum drug concentration</td>
</tr>
<tr>
<td>TT</td>
<td>treatment termination</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>VGPR</td>
<td>very good partial response</td>
</tr>
<tr>
<td>VWF</td>
<td>von Willebrand Factor</td>
</tr>
<tr>
<td>Vz/F</td>
<td>volume of distribution</td>
</tr>
<tr>
<td>WM</td>
<td>Waldenström macroglobulinemia</td>
</tr>
</tbody>
</table>
# STUDY SYNOPSIS

<table>
<thead>
<tr>
<th>Protocol Number:</th>
<th>ACE-WM-001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Drug:</td>
<td>ACP-196 (acalabrutinib)</td>
</tr>
<tr>
<td>Protocol Title:</td>
<td>An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia³</td>
</tr>
<tr>
<td>Phase:</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Comparator:</td>
<td>None</td>
</tr>
</tbody>
</table>

**Background and Rationale for Study**

Clinical studies have shown that targeting the B-cell receptor (BCR) signaling pathway by inhibiting Bruton tyrosine kinase (BTK) produces significant clinical benefit in patients with non-Hodgkin lymphoma, including Waldenström macroglobulinemia (WM). Ibrutinib (IMBRUVICA®), an oral, small-molecule BTK inhibitor has been approved for the treatment for chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and WM.

Acerta Pharma BV (Acerta Pharma) has developed a novel BTK inhibitor, acalabrutinib, that achieves significant oral bioavailability and potency in preclinical models.

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.

**Study Design:**

This study is a multicenter (approximately 30 global centers) open-label clinical study evaluating the safety and efficacy of acalabrutinib 100 mg twice a day (BID) in subjects with previously treated WM (N=76) using a Simon’s optimal 2-stage design. In addition, a small cohort (N=8–12) of subjects with treatment-naïve WM will be enrolled as an exploratory cohort to determine the preliminary safety and efficacy of acalabrutinib in this patient population. In The Netherlands and France, enrollment for the untreated WM cohort will begin after efficacy has been confirmed in Stage 1 of the Simon’s optimal 2-stage design; in other locations, both previously treated and untreated cohorts will be enrolled simultaneously.

Twenty-eight days of study drug administration is 1 cycle. Treatment with acalabrutinib may be continued until disease progression or an unacceptable drug-related toxicity occurs. Dose modification provisions are provided in the protocol. Note: Temporary withholding of study drug for as little as 7 days can cause a transient worsening of disease and/or of constitutional symptoms. Refer to Section 3.8 for more information on assessing disease progression under these circumstances. A

³In Italy only, the original protocol title “An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia” remains in effect.
treatment termination (TT) visit is required for safety assessments for any subjects who permanently discontinue study drug for any reason (except for death, loss to follow-up or withdrawal of consent), including disease progression, and should be scheduled within 7 days of his or her last dose of study drug, if possible. In addition to the TT visit, all subjects who discontinue acalabrutinib will have a safety follow-up (SFU) visit 30 (+7) days after the last dose of study drug to monitor for resolution or progression of adverse events (AEs) and to document the occurrence of any new events, regardless of whether the subject receives a new anticancer therapy or demonstrates disease progression within this timeframe. Refer to Section 4.4 for information on follow-up for progression and survival.

All subjects will have standard hematology, chemistry, and urinalysis safety panels done at screening. Once dosing commences (Day 1), all subjects will be evaluated for safety, including serum chemistry and hematology according to Appendix 4. Pharmacokinetic (PK) testing will be done in Cycle 1 only, and pharmacodynamic (PD) testing will be done in Cycle 1 and Cycle 2. PK/PD will be done on all subjects in the treatment-naive cohort and on up to 12 subjects in the previously treated cohort.

Assessments for efficacy will be completed throughout the study as per Appendix 4.

A single, interim analysis (see Section 5.6) of overall response rate (ORR) will be performed when subjects from Stage 1 (28 subjects) are evaluable for response.

Refer to Appendix 4 for a comprehensive list of study assessments and their timing. The end of study is defined as the last subject’s last visit. The sponsor may terminate the study at any time. Subjects who are deriving clinical benefit from acalabrutinib may continue on study until a rollover protocol is available. The study duration is expected to be approximately 6 years from enrollment of the last subject. A study schema is provided at the end of this synopsis.

<table>
<thead>
<tr>
<th>Study Objectives:</th>
<th>Primary Objective:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>To determine the ORR of acalabrutinib in subjects with WM as assessed by the investigator.</td>
</tr>
</tbody>
</table>

**Secondary Objectives:**

- To determine the duration of overall response (DOR) of acalabrutinib assessed by the investigator
- To determine the progression-free survival (PFS) of acalabrutinib assessed by the investigator
- To determine the overall survival (OS) of acalabrutinib
To characterize the PK profile of acalabrutinib
To characterize the safety of acalabrutinib
To evaluate the effect of acalabrutinib in health-related quality of life

**Exploratory Objective:**
To evaluate the PD effects of acalabrutinib

### Study Endpoints

<table>
<thead>
<tr>
<th>Co-Primary endpoints:</th>
<th>Secondary endpoints:</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR, defined as a subject achieving a minor response (MR) or better according to the response assessment criteria for WM (Owen 2013), as assessed by the investigator</td>
<td>Efficacy:</td>
</tr>
<tr>
<td>ORR, defined as a subject achieving a MR or better according to the response assessment criteria defined by modified 3rd International Workshops on Waldenström Macroglobulinemia (IWWM) workshop criteria (Kimby 2006), as assessed by the investigator</td>
<td>• DOR assessed by the investigator using response assessment criteria for WM (Owen 2013) and modified 3rd IWWM workshop criteria (Kimby 2006)</td>
</tr>
<tr>
<td>• ORR, defined as a subject achieving a MR or better according to the response assessment criteria defined by modified 3rd International Workshops on Waldenström Macroglobulinemia (IWWM) workshop criteria (Kimby 2006), as assessed by the investigator</td>
<td>• PFS assessed by the investigator using response assessment criteria for WM (Owen 2013) and modified 3rd IWWM workshop criteria (Kimby 2006)</td>
</tr>
<tr>
<td>• OS</td>
<td>• OS</td>
</tr>
<tr>
<td>• Effect of acalabrutinib on peripheral T/B/natural killer (NK) cell counts</td>
<td>• Effect of acalabrutinib on serum immunoglobulin levels</td>
</tr>
<tr>
<td>• Effect of acalabrutinib on serum immunoglobulin levels</td>
<td>Safety:</td>
</tr>
<tr>
<td>• Frequency, severity, and relatedness of AEs</td>
<td>• Frequency, severity, and relatedness of AEs</td>
</tr>
<tr>
<td>• Frequency of AEs requiring discontinuation of study drug or dose reductions</td>
<td>Pharmacokinetics:</td>
</tr>
<tr>
<td>Pharmacokinetics:</td>
<td>• Plasma pharmacokinetics of acalabrutinib</td>
</tr>
<tr>
<td>• Plasma pharmacokinetics of acalabrutinib</td>
<td>Patient-Reported Outcomes (PRO):</td>
</tr>
<tr>
<td>• BTK occupancy and biologic markers of B-cell function</td>
<td>• Health-related quality of life</td>
</tr>
</tbody>
</table>

**Exploratory endpoints:**

**Pharmacodynamics:**
• BTK occupancy and biologic markers of B-cell function
<table>
<thead>
<tr>
<th>Pharmacokinetic Parameters:</th>
<th>The plasma PK of acalabrutinib will be characterized using noncompartmental analysis. The following PK parameters will be calculated, whenever possible, from plasma concentrations of acalabrutinib:</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC₀⁻last</td>
<td>Area under the plasma concentration-time curve calculated using linear trapezoidal summation from time 0 to time last, where “last” is the time of the last measurable concentration (Cₜ).</td>
</tr>
<tr>
<td>AUC₀⁻₁₂</td>
<td>Area under the plasma concentration-time curve from 0 to 12 hours, calculated using linear trapezoidal summation.</td>
</tr>
<tr>
<td>AUC₀⁻∞</td>
<td>Area under the plasma concentration-time curve from 0 to infinity, calculated using the formula: AUC₀⁻∞ = AUC₀⁻last + Cₜ / λ₂, where λ₂ is the apparent terminal elimination rate constant.</td>
</tr>
<tr>
<td>AUC₀⁻₂₄calc</td>
<td>Area under the plasma concentration-time curve from 0 to 24 hours, calculated by doubling the value for AUC₀⁻₁₂</td>
</tr>
<tr>
<td>Cₘₐₓ</td>
<td>Maximum observed plasma concentration</td>
</tr>
<tr>
<td>Tₘₐₓ</td>
<td>Time of the maximum plasma concentration (obtained without interpolation)</td>
</tr>
<tr>
<td>t₁/₂</td>
<td>Terminal elimination half-life (whenever possible)</td>
</tr>
<tr>
<td>λ₂</td>
<td>Terminal elimination rate constant (whenever possible)</td>
</tr>
<tr>
<td>CL/F</td>
<td>Oral clearance</td>
</tr>
<tr>
<td>Vz/F</td>
<td>Oral volume of distribution</td>
</tr>
</tbody>
</table>

| Pharmacodynamic Parameters: | The occupancy of BTK by acalabrutinib will be measured in peripheral blood mononuclear cells and in bone marrow, when available, with the aid of a biotin-tagged acalabrutinib analogue probe. The effect of acalabrutinib on biologic markers of B-cell function will also be evaluated. |

| Sample Size: | The Simon’s optimal 2-stage portion of the study for evaluation of efficacy in subjects with previously treated WM will be approximately 76 subjects. The exploratory cohort in subjects with treatment-naive WM will enroll approximately 8 to 12 subjects. |

| Inclusion Criteria: | Men and women ≥18 years of age.  
Previously treated cohort only: A confirmed diagnosis of WM, which has relapsed after, or been refractory to ≥1 prior therapy for WM and which requires treatment. |
- **Treatment-naive cohort only:** A confirmed diagnosis of treatment-naive WM in subjects who require treatment and do not want to receive chemoimmunotherapy or have comorbidities that would preclude chemoimmunotherapy such as:
  - Symptomatic hyperviscosity with an immunoglobulin (Ig) M ≥5,000 mg/dL
  - Disease-related neuropathy
- Serum concentration of IgM, as measured by serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), that exceeds the upper limits of normal or measurable nodal WM (defined as the presence of ≥1 lymph node that measures ≥2.0 cm in the longest diameter and ≥1.0 cm in the longest perpendicular diameter).
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
- Women who are sexually active and can bear children must agree to use highly effective forms of contraception during the study and for 2 days after the last dose of acalabrutinib. Highly effective forms of contraception are defined in Section 3.7.7.
- Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).

<table>
<thead>
<tr>
<th>Exclusion Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥2 years or which will not limit survival to &lt;2 years. Note: These cases must be discussed with the medical monitor.</td>
</tr>
<tr>
<td>A life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk.</td>
</tr>
<tr>
<td>Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York</td>
</tr>
</tbody>
</table>
Heart Association Functional Classification, or corrected QT interval (QTc) >480 msec.

- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

- Any immunotherapy within 4 weeks of first dose of study drug.

- For subjects with recent chemotherapy or experimental therapy, the first dose of study drug must occur after 5 times the half-life of the agent(s).

- Prior exposure to a BCR inhibitor (e.g., BTK, phosphoinositide-3 kinase [PI3K], or spleen tyrosine kinase [SYK] inhibitors) or B-cell lymphoma 2 (BCL-2) inhibitor (e.g., ABT-199).

- Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids, for treatment of WM or other conditions. Note: Subjects may use topical or inhaled corticosteroids or low-dose steroids (≤10 mg of prednisone or equivalent per day) as therapy for comorbid conditions. During study participation, subjects may also receive systemic or enteric corticosteroids as needed for treatment-emergent comorbid conditions.

- Grade ≥2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation.

- Known history of HIV or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.

- Major surgery within 4 weeks before first dose of study drug.

- Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.

- History of a bleeding diathesis (e.g., hemophilia, von Willebrand disease).

- History of stroke or intracranial hemorrhage within 6 months before the first dose of acalabrutinib.

- Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonist (e.g., phenprocoumon) within 28 days of first dose of study drug.

- Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).

- Absolute neutrophil count (ANC) <0.75 x 10^9/L or platelet count <50 x 10^9/L. For subjects with disease involvement
in the bone marrow, ANC <0.50 x 10^9/L or platelet count <30 x 10^9/L.

- Creatinine >2.5 x institutional ULN; total bilirubin >2.5 x ULN; or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3.0 x ULN.
- Lactating or pregnant.
- Concurrent participation in another therapeutic clinical study.

**Dosage Form and Strength:**

Acalabrutinib is provided as hard gelatin capsules prepared using standard pharmaceutical grade excipients.

**Dose Regimen/Route of Administration:**

Acalabrutinib is an orally administered product. Acalabrutinib can be administered with or without food.

Acalabrutinib 100 mg administered BID, 12 hours apart (BID dosing = total daily dose of 200 mg). It is recommended that acalabrutinib be taken as close to the scheduled time as possible (preferably within 1 hour). However, if a dose is missed, it can be taken up to 3 hours after the scheduled time with a return to the normal schedule with the following dose.

**Concomitant Medications:**

The effect of agents that reduce gastric acidity (antacids or proton-pump inhibitors) on acalabrutinib absorption was evaluated in a healthy volunteer study (ACE-HV-004). Results from this study indicate that subjects should avoid the use of calcium carbonate containing drugs or supplements for a period of at least 2 hours before and at least 2 hours after taking acalabrutinib. Use of omeprazole, esomeprazole, lansoprazole or any other proton-pump inhibitors while taking acalabrutinib is not recommended due to a potential decrease in study drug exposure. However, the decision to treat with proton-pump inhibitors during the study is at the investigator’s discretion, with an understanding of the potential benefit to the subject’s gastrointestinal condition and a potential risk of decreased exposure to acalabrutinib.

Although the effect of H2-receptor antagonists (such as famotidine or ranitidine) on acalabrutinib absorption has not been evaluated, if treatment with an H2-receptor antagonist is required, the H2-receptor antagonist should be taken approximately 2 hours after an acalabrutinib dose.

Concomitant use of strong inhibitors/inducers of cytochrome P450 (CYP) 3A should be avoided when possible. If a subject requires a strong or moderate CYP3A inhibitor while on study, monitor the subject closely for potential toxicities.
<table>
<thead>
<tr>
<th>Statistical Methods:</th>
<th>Simon's optimal 2-stage design for assessment of efficacy in previously treated subjects:</th>
</tr>
</thead>
</table>

Exploratory cohort for assessment of efficacy in treatment-naive subjects:

No formal statistical tests of hypotheses will be performed. Eight to 12 evaluable subjects will be enrolled in this cohort for evaluation of preliminary efficacy and safety in this patient population.

Descriptive statistics (including means, standard deviations, and medians for continuous variables and proportions for discrete variables) will be used to summarize data, as appropriate.
1.0 BACKGROUND INFORMATION

1.1 Role of BTK in Lymphoid Cancers

BTK is a non-receptor enzyme of the Tec kinase family that is expressed among cells of hematopoietic origin, including B cells, myeloid cells, mast cells and platelets, where it regulates multiple cellular processes including proliferation, differentiation, apoptosis, and cell migration (Mohamed 2009, Bradshaw 2010). Functional null mutations of BTK in humans cause the inherited disease, X-linked agammaglobulinemia, which is characterized by a lack of mature peripheral B cells (Vihinen 2000). Conversely, BTK activation is implicated in the pathogenesis of several B-cell malignancies (Buggy 2012). Taken together, these findings have suggested that inhibition of BTK may offer an attractive strategy for treating B-cell neoplasms.

Ibrutinib (IMBRUVICA®), an oral, small-molecule BTK inhibitor has been approved for the treatment for CLL, mantle cell lymphoma (MCL), and WM.

While highly potent in inhibiting BTK, ibrutinib has also shown in vitro activity against other kinases with a cysteine in the same position as Cys481 in BTK to which the drug covalently binds. The inhibition of epidermal growth factor receptor (EGFR) is also observed in cellular assays and may be the cause of ibrutinib-related AEs of diarrhea and rash (IMBRUVICA® prescribing information). In addition, ibrutinib is a substrate for CYP3A4; inhibition of CYP3A causes a 29-fold increase in Cmax and 24-fold increase in AUC for ibrutinib (IMBRUVICA® prescribing information). This increases the possibility of drug-drug interactions in combination therapies with drugs currently used in management of subjects with cancer. These liabilities support the development of alternative BTK inhibitors for use in the therapy of B-cell malignancies.

Chemical optimization, pharmacologic characterization, and toxicologic evaluation have led to identification of acalabrutinib (also known as ACP-196), an orally bioavailable, new chemical entity that covalently inhibits BTK and shows encouraging activity and acceptable safety in nonclinical studies. Within the class of BTK inhibitors, acalabrutinib is a more selective inhibitor of BTK than ibrutinib. Key nonclinical differentiators of acalabrutinib versus ibrutinib are:

- Acalabrutinib has been evaluated against ibrutinib in EGFR-expressing cell lines. Ibrutinib is a potent covalent inhibitor of EGFR (EC50=5.3 nM). Acalabrutinib did not inhibit EGFR, even at the highest concentration tested (10 μM).
• Acalabrutinib and ibrutinib have been evaluated in NK cell functional assays. While ibrutinib inhibits NK cell functions including antibody-dependent cellular cytotoxicity (ADCC), lytic granule release and cytokine production (Kohrt 2014), the in vitro functional activity of acalabrutinib-treated NK cells was preserved.

• Acalabrutinib has been evaluated against ibrutinib in an in vivo thrombus formation model. Platelets from CLL patients treated with acalabrutinib had similar thrombus formation dynamics as platelets from healthy volunteers, while platelets from ibrutinib-treated CLL patients had impaired thrombus formation.

The nonclinical and toxicology results of acalabrutinib suggest it may have an improved therapeutic window relative to ibrutinib; it may be more readily combined with other agents for the treatment of cancer.

1.2 Preclinical Studies
Summaries of preclinical studies are provided below. For more detailed information, refer to the acalabrutinib Investigator Brochure.

1.2.1 Chemistry
Acalabrutinib is an imidazopyrazine analogue with a molecular weight of 465.5 g/mol. The compound has 1 stereogenic center and acalabrutinib is the S-enantiomer. Acalabrutinib is orally bioavailable in humans and is suitable for formulating in capsules. For clinical testing, acalabrutinib has been manufactured and formulated according to current Good Manufacturing Practices.

Calquence® has been approved in the United States on October 31, 2017 and other markets for the treatment of adult patients with MCL who have received at least 1 prior therapy.

1.2.2 Mechanism of Action of Acalabrutinib
Acalabrutinib was specifically designed to be a more potent and selective inhibitor of BTK to avoid off-target side effects as seen with ibrutinib. When profiled against 395 human kinases, acalabrutinib is more selective than ibrutinib (Covey 2015). For additional details, refer to the acalabrutinib Investigator Brochure.

1.2.3 Dog Lymphoma Study
Spontaneous canine B-cell lymphoma shares many characteristics with human non-Hodgkin lymphoma, including diagnostic classifications and response to BTK inhibition
The life expectancy in untreated animals with aggressive disease is ~6 weeks, thus enabling rapid assessment of drug efficacy (Vail 2004). Acalabrutinib was evaluated in a dose-escalation study in canine spontaneous B-cell lymphoma (Harrington 2016). Twenty dogs were enrolled in the study and treated with acalabrutinib at dosages of 2.5 to 20 mg/kg every 12 or 24 hours. Acalabrutinib was generally well tolerated, with AEs consisting primarily of grade 1 or 2 anorexia, weight loss, vomiting, diarrhea and lethargy. Per Veterinary Cooperative Oncology Group criteria for assessment of response in peripheral nodal lymphoma (Vail 2010), the ORR was 25% (5/20) with a median PFS of 22.5 days. Clinical benefit was observed in 30% (6/20) of dogs. These findings suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma. These findings are similar to the responses (i.e., 1 dog with partial response (PR) out of 5 dogs treated with suspected or confirmed diffuse large B-cell lymphoma) observed with ibrutinib in dogs with spontaneous B-cell lymphoma (Honigberg 2010).

1.2.4 Acalabrutinib and Antibody-dependent Cell-mediated Cytotoxicity

As acalabrutinib is not an inhibitor of interleukin-2-inducible T-cell kinase (ITK) kinase, it is expected to have less activity against non-malignant cells that require ITK for development and functional activation, such as T and NK cells. ITK kinase is required for Fc receptor-stimulated NK cell function including calcium mobilization, granule release, and overall ADCC. Anti-CD20 antibodies are standard of care drugs, often as part of combination regimens, for the treatment of CD20+ B-cell malignancies; obinutuzumab has been specifically designed to increase Fc interactions and promote ADCC and phagocytosis of malignant CD20+ cells. Ibrutinib has been evaluated for effects on NK activity, including ADCC, using in vitro assays of cytokine release, lytic granule release, and cellular cytotoxicity (Kohrt 2014). In contrast to more specific BTK inhibitors, ibrutinib inhibited all these NK cell functions, and impaired NK activity against rituximab-coated autologous CLL cells and in mouse tumor models requiring Fc-mediated effector functions (Kohrt 2014). Acalabrutinib was tested in ADCC and natural cytotoxicity assays, using cells from healthy donors. In these in vitro tests, NK cell function was preserved with acalabrutinib treatment, whereas ibrutinib inhibited functional activity, including natural cytotoxicity against K562 cells.
Peripheral blood mononuclear cells were cultured with $^{51}$Cr labelled K562 targets at an E:T ratio of 100:1 for 4 hours. Cytotoxicity was evaluated by scintillation counting of supernatants. Treatment, dose and interaction effect were significant in 2-way ANOVA (n=5 healthy donors; ibrutinib v. acalabrutinib p<0.0001; all ibrutinib doses p<0.0001 compared with control; p=0.0117 for control vs. acalabrutinib 1 µM, other acalabrutinib doses not statistically different from control condition).

1.2.5 Acalabrutinib and Thrombus Formation
Ibrutinib is associated with an increased risk of bleeding (Kamel 2014). Hence, the effects of acalabrutinib and ibrutinib were evaluated on human platelet-mediated thrombus formation by using the in vivo human thrombus formation in a von Willebrand Factor (VWF$^{HA1}$) murine model, which has been previously described (Chen 2008). The in vivo function of platelets isolated from blood of healthy volunteers (n=5), CLL subjects treated with 420 mg once a day (QD) ibrutinib (n=5) or CLL subjects treated with 100 mg BID acalabrutinib (n=3) was evaluated in the VWF$^{HA1}$ model. Results from this study showed a reduction in platelet-vessel wall interactions of platelets from ibrutinib-treated CLL subjects, but not of those from CLL subjects treated with acalabrutinib (Byrd 2016).
Figure 2. In Vivo Thrombus Formation

Platelets from patients treated with ibrutinib 420 mg once per day (n=5) or acalabrutinib 100 mg twice per day (n=3) were evaluated for their ability to support thrombus formation in laser injured arterioles of VWF^A1 mice. Freshly isolated platelets from healthy volunteers (n=5) were used as non-drug treated controls. A minimum of 4 arterioles per mouse was used to assess thrombus formation for each patient/volunteer sample. Median fluorescence intensity as a function of time is provided in the figure (shading denotes standard error of the median).

1.2.6 Safety Pharmacology

In vitro and in vivo safety pharmacology studies with acalabrutinib have demonstrated a favorable nonclinical safety profile.

When screened at 10 µM in binding assays evaluating interactions with 80 known pharmacologic targets such as G-protein-coupled receptors, nuclear receptors, proteases, and ion channels, acalabrutinib shows significant activity only against the A3 adenosine receptor; follow-up dose-response experiments indicated an IC$_{50}$ of 4.5 µM, suggesting a low clinical risk of off-target effects.

The in vitro effect of acalabrutinib on human ether-à-go-go-related gene (hERG) channel activity was investigated in vitro in human embryonic kidney cells stably transfected with hERG. Acalabrutinib inhibited hERG channel activity by 25% at 10 µM, suggesting a low clinical risk that acalabrutinib would induce clinical QT prolongation as predicted by this assay.

Acalabrutinib was well tolerated in standard in vivo Good Laboratory Practices studies of pharmacologic safety. A functional observation battery in rats at doses through 300 mg/kg (the highest dose level) revealed no adverse effects on neurobehavioral effects or body temperature at any dose level. A study of respiratory function in rats also
indicated no treatment-related adverse effects at doses through 300 mg/kg (the highest
dose level). In a cardiovascular function study in awake telemeterized male beagle
dogs, single doses of acalabrutinib at dose levels through 30 mg/kg (the highest dose
level) induced no meaningful changes in body temperature, cardiovascular, or ECG
(including QT interval) parameters. The results suggest that acalabrutinib is unlikely to
cause serious off-target effects or adverse effects on critical organ systems.

1.2.7 Drug-Drug Interaction Potential

Based on available preclinical and clinical data, acalabrutinib is cleared by multiple CYP
and non-CYP metabolic pathways. CYP3A-mediated oxidation appears to be a major
route of metabolism in humans. In excretion studies in preclinical species, metabolites
were mainly related to direct conjugation of acalabrutinib with glutathione and
conjugation with glutathione in vitro was mediated primarily by human glutathione
transferases GSTM1 and GSTM2. Metabolites also arose from oxidation (CYP3A) and
amide hydrolysis, or combinations thereof.

In a healthy volunteer study (ACE-HV-001), the effect of co-administration of a potent
CYP3A and P-glycoprotein inhibitor, itraconazole, on the plasma levels of acalabrutinib
was evaluated. The mean plasma acalabrutinib C_{\text{max}} and AUC_{0-\text{inf}} values increased
3.7-fold and 5.1-fold, respectively, in the presence of itraconazole relative to no
pretreatment. In a healthy volunteer study (ACE-HV-004) rifampin, a strong CYP3A
inducer, dosed at 600 mg QD for 9 days decreased AUC to 23% of values obtained with
acalabrutinib dosed alone. Refer to Section 3.6.2 for detailed recommendations on
concomitant administration of acalabrutinib with strong CYP3A inhibitors or inducers.

Results from a healthy volunteer study (ACE-HV-004) also showed drugs that reduce
gastric acidity can lower acalabrutinib exposure. Refer to Section 3.6.3 for detailed
recommendations regarding co-administration of acalabrutinib with agents that reduce
gastric acidity.

Acalabrutinib is unlikely to be a perpetrator of a drug-drug interaction at the level of
inhibition or induction of CYP isoforms.

Results from drug transporter studies suggest that acalabrutinib is not anticipated to alter
the PK of other therapeutic agents that are substrates for multidrug resistance protein 1,
organic-anion-transporting polypeptide (OATP)1B1, OATP1B3, OAT1, OAT3, and
OCT2. Acalabrutinib is a substrate and inhibitor of breast cancer resistance protein and
may alter the PK of coadministered breast cancer resistance protein substrates.
Refer to the acalabrutinib Investigator Brochure for additional details on acalabrutinib PK; absorption, distribution, metabolism, and excretion; and drug interaction studies.

1.2.8 In Vivo General Toxicology
The systemic toxicity of acalabrutinib has been fully evaluated in repeat-dose sub-chronic studies in mice, rats and dogs, reproductive toxicity studies in rats and rabbits, and ongoing chronic studies in rats and dogs. The pivotal GLP studies were 28- and 91-day repeat dose studies in rats and dogs, each with recovery periods to assess the reversibility of observed changes.

In rats, 100 mg/kg/day was selected initially to represent the highest non-severely toxic dose; however, in subsequent studies the 100 mg/kg/day dose level was determined to be a no observable adverse effect level (NOAEL). In rats, the target organs of toxicity were the kidney, liver and heart.

The NOAEL in the dog was 30 mg/kg/day; dose levels higher than 30 mg/kg/day were not tolerated. In dogs, the target organs of toxicity, observed only at doses exceeding the maximum tolerated dose, were the kidney and liver. Heart findings were also observed in 2 dogs with kidney toxicity, which were interpreted as possibly secondary to uremia, as has been reported for this species.

In rats and dogs, no adverse ECG or histopathologic cardiovascular effects were noted at the planned conclusion of the sub-chronic studies or in the rat chronic toxicity study. However, in 5 of 6 rats from the 4-week study that died early, slight to moderate necrosis of the myocardium and/or white blood cell infiltration/inflammation of the myocardium were noted on microscopic examination of the hearts.

1.3 Clinical Studies
A list of completed and ongoing clinical studies is provided in the acalabrutinib Investigator Brochure.

1.3.1 Pharmacokinetics and Pharmacodynamics of Acalabrutinib in Clinical Pharmacology Studies
PK properties of acalabrutinib in healthy adult volunteers were evaluated after oral administration of 2 daily divided doses of 2.5 to 50 mg and a single dose of 100 mg (ACE-HV-001). Acalabrutinib $T_{\text{max}}$ values were between 0.5 and 1.0 hour for all dose cohorts, and were independent of dose level. Mean $t_{1/2}$ values ranged from 0.97 hour to 2.1 hours. Exposure increases were approximately linear from 25 mg up to and beyond
therapeutic doses of 100 or 200 mg. Rapid elimination was observed. Acalabrutinib does not accumulate with daily administration. Similar PK results were observed in subjects with CLL treated with acalabrutinib. In healthy subjects and subjects with CLL, dose-related increases in BTK occupancy were attained, and relatively high BTK occupancy (>90%) was observed with a single dose of 100 mg.

Administration of acalabrutinib with a high-fat, high-calorie meal did not have a clinically significant effect on exposure so acalabrutinib can be taken without regard to meals. In healthy volunteer studies, agents that lowered gastric acidity (e.g., calcium carbonate and omeprazole) lowered exposure of concomitantly administered acalabrutinib. Acalabrutinib is unlikely to be a perpetrator of a drug-drug interaction at the level of inhibition or induction of CYP isoforms. However, the mean plasma acalabrutinib $C_{\text{max}}$ and AUC values increased 3.7- and 5.1-fold, respectively, in the presence of itraconazole, a strong CYP3A inhibitor, relative to no pretreatment. Rifampin, a strong CYP3A inducer, dosed at 600 mg QD for 9 days decreased AUC to 23% of values obtained with acalabrutinib dosed alone.

For more detailed information on acalabrutinib clinical pharmacology studies, refer to the acalabrutinib Investigator Brochure.

### 1.3.2 Clinical Experience

As of 30 December 2018, acalabrutinib has been administered to over 2600 participants in clinical studies including subjects with hematologic malignancies, solid tumors, or rheumatoid arthritis, and participants who are healthy volunteers or with mild to moderate hepatic impairment. No serious adverse events (SAEs) have been reported in the completed hepatic impairment study (Study ACE-HI-001) or in the healthy volunteer studies. For more detailed information on the clinical experience for acalabrutinib, refer to the Investigator Brochure.

Study ACE-CL-001 (NCT02029443) is an ongoing, nonrandomized, sequential group, dose-escalation Phase 1/2 study in subjects with CLL, including subjects with relapsed/refractory CLL, treatment-naive subjects, ibrutinib-intolerant subjects, and subjects with Richter’s syndrome or prolymphocytic leukemia transformation. As of 01 December 2017, 134 subjects with relapsed/refractory CLL have been evaluated for tumor response based on International Working Group response criteria (Hallek 2008) as recently updated (Cheson 2012) to include PR with treatment-induced lymphocytosis. With a median time on study of 31.8 months, an ORR of 96.2% has been observed in
these subjects. Preliminary data through 04 September 2018 are also available for 99 enrolled subjects with treatment-naïve CLL. With a median time on study of 41.6 months, the ORR was 99\% in these subjects.

1.4 Benefit/Risk

Acalabrutinib is a potent, orally administered small molecule inhibitor of BTK. A PK/PD study has been completed with acalabrutinib in healthy volunteers (ACE-HV-001; Section 1.3.2). The safety results showed no identified safety risks in healthy subjects receiving 1 or 2 days of acalabrutinib ≤100 mg. In Study ACE-CL-001, no dose-limiting toxicities were reported at dosages of ≤400 mg QD or 100 and 200 mg BID. Based on the results for subjects with CLL and other B-cell malignancies, the evaluation of acalabrutinib in subjects with WM is warranted.

1.5 Summary and Conclusions

The design and conduct of this study are supported by an understanding of the natural history and current therapies for subjects with lymphoid cancers; knowledge of the efficacy and safety of the first-generation BTK inhibitor (ibrutinib) in subjects with hematologic cancers; and the available nonclinical and clinical information regarding acalabrutinib.

2.0 STUDY OBJECTIVES

2.1 Primary Objective
To determine the ORR of acalabrutinib in subjects with WM as assessed by the investigator.

2.2 Secondary Objectives

- To determine the DOR of acalabrutinib assessed by the investigator
- To determine the PFS of acalabrutinib assessed by the investigator
- To determine the OS of acalabrutinib
- To characterize the PK profile of acalabrutinib
- To characterize the safety of acalabrutinib
- To evaluate the effect of acalabrutinib in health-related quality of life

2.3
3.0 STUDY DESIGN

3.1 Description of Study
This study is a multicenter (approximately 30 global centers), open-label clinical study evaluating the safety and efficacy of acalabrutinib 100 mg BID in subjects with previously treated WM (N=76) using a Simon's optimal 2-stage design (Simon 1989). In addition, a small cohort (N=8–12) of subjects with treatment-naive WM will be enrolled as an exploratory cohort to determine the preliminary safety and efficacy of acalabrutinib in this patient population. In The Netherlands and France, enrollment for the untreated WM cohort will begin after efficacy has been confirmed in Stage 1 of the Simon's optimal 2-stage design; in other locations, both previously treated and untreated cohorts will be enrolled simultaneously.

Twenty-eight days of study drug administration is 1 cycle. Treatment with acalabrutinib may be continued until disease progression or an unacceptable drug-related toxicity occurs. Dose modification provisions are provided in the protocol (Section 3.5.6). Note: Temporary withholding of study drug for as little as 7 days can cause a transient worsening of disease and/or of constitutional symptoms. Refer to Section 3.8 for more information on assessing disease progression under these circumstances. A TT visit is required for safety assessments for any subjects who permanently discontinue study drug for any reason (except for death, loss to follow-up, or withdrawal of consent), including disease progression, and should be scheduled within 7 days of his or her last dose of study drug, if possible. In addition to the TT visit, all subjects who discontinue acalabrutinib will have a SFU visit 30 (+7) days after the last dose of study drug to monitor for resolution or progression of AEs and to document the occurrence of any new events, regardless of whether the subject receives a new anticancer therapy or demonstrates disease progression within this timeframe. Refer to Section 4.4 for information on follow-up for progression and survival.

All subjects will have standard hematology, chemistry, and urinalysis safety panels done at screening. Once dosing commences (Day 1), all subjects will be evaluated for safety, including serum chemistry and hematology according to Appendix 4. PK testing will be done in Cycle 1 only and PD testing will be done in Cycle 1 and Cycle 2. PK/PD will be done on all subjects in the treatment-naive cohort and on up to 12 subjects in the previously treated cohort.

Assessments for efficacy will be completed throughout the study as per Appendix 4.
A single interim analysis (see Section 5.6) of ORR will be performed when subjects from Stage 1 (28 subjects) are evaluable for response.

Refer to Appendix 4 for a comprehensive list of study assessments and their timing. The end of study is defined as the time the last subject’s last visit. The sponsor may terminate the study at any time. Subjects who are deriving clinical benefit from acalabrutinib may continue on study until a rollover protocol is available. The study duration is expected to be approximately 6 years from enrollment of the last subject.

3.2 Study Endpoints and Parameters

3.2.1 Co-Primary Endpoints

- ORR, defined as a subject achieving a MR or better according to the response assessment criteria for WM (Owen 2013), as assessed by the investigator

- ORR, defined as a subject achieving a MR or better according to the response assessment criteria defined by modified 3rd IWWM workshop criteria (Kimby 2006), as assessed by the investigator

3.2.2 Secondary Endpoints

Efficacy:

- DOR assessed by the investigator using response assessment criteria for WM (Owen 2013) and modified 3rd IWWM workshop criteria (Kimby 2006)

- PFS assessed by the investigator using response assessment criteria for WM (Owen 2013) and modified 3rd IWWM workshop criteria (Kimby 2006)

- OS

- Effect of acalabrutinib on peripheral T/B/NK cell counts

- Effect of acalabrutinib on serum immunoglobulin levels

Safety:

- Frequency, severity, and relatedness of AEs

- Frequency of AEs requiring discontinuation of study drug or dose reductions

Pharmacokinetics:

- Plasma pharmacokinetics of acalabrutinib

PRO:

- Health-related quality of life
3.2.4 Safety Parameters
The safety of acalabrutinib will be characterized by the type, frequency, severity, and relationship to study drug of any treatment-emergent AEs or abnormalities of laboratory tests; SAEs; or AEs leading to discontinuation or dose reduction of study treatment.

For consistency of interpretation, AEs will be coded using the MedDRA, and the severity of AEs and laboratory abnormalities will be graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 or higher. Standard definitions for seriousness will be applied (see Section 6.1).

3.2.5 Pharmacokinetic and Pharmacodynamic Parameters
Standard PK parameters for acalabrutinib in plasma will be evaluated in this study. A full description of the PK parameters is provided in Section 5.5.4.

The occupancy of BTK by acalabrutinib will be measured in peripheral blood mononuclear cells and bone marrow, when available, with the aid of a biotin-tagged acalabrutinib analogue probe. The effect of acalabrutinib on biologic markers of B-cell function will also be evaluated.

3.3 Rationale for Study Design and Dosing Regimen
A total daily dose of 200 mg of acalabrutinib (100 mg BID) has been selected for this study. Preliminary PK data from ACE-CL-001 as described in Section 1.3.2 suggest a plateauing of exposure after 250 mg QD. PD results from this study also show similar BTK occupancy for 250 and 400 mg QD at 24 hours. Therefore, based on PK/PD, safety, and efficacy results of the Phase 1/2 study, a 200-mg total daily dose (100-mg capsules administered BID) will be evaluated. For the most recent information on acalabrutinib study results and dosing rationale, refer to the acalabrutinib Investigator Brochure.
3.4 Selection of Study Population

3.4.1 Inclusion Criteria

Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:

1. Men and women ≥ 18 years of age.
2. Previously treated cohort only: A confirmed diagnosis of WM, which has relapsed after, or been refractory to ≥1 prior therapy for WM and which requires treatment.
3. Previously untreated cohort only: A confirmed diagnosis of previously untreated WM in subjects who require treatment and do not want to receive chemoimmunotherapy or have comorbidities that would preclude chemoimmunotherapy such as:
   - Symptomatic hyperviscosity with an IgM ≥5,000 mg/dL
   - Disease-related neuropathy
4. Serum concentration of IgM, as measured by SPEP and IFE, that exceeds the upper limits of normal or measurable nodal WM (defined as the presence of ≥1 lymph node that measures ≥2.0 cm in the longest diameter and ≥1.0 cm in the longest perpendicular diameter).
5. ECOG performance status of ≤2.
6. Women who are sexually active and can bear children must agree to use highly effective forms of contraception during the study and for 2 days after the last dose of acalabrutinib. Highly effective forms of contraception are defined in Section 3.7.7.
7. This criterion was removed as of Protocol Amendment 7.
8. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
9. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).

3.4.2 Exclusion Criteria

Subjects will be ineligible for this study if they meet any of the following criteria:

1. Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥2 years or which will not limit survival to <2 years. Note: These cases must be discussed with the medical monitor.
2. A life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk.
3. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of...
screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or QTc >480 msec.

4. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

5. Any immunotherapy within 4 weeks of first dose of study drug.

6. For subjects with recent chemotherapy or experimental therapy, the first dose of study drug must occur after 5 times the half-life of the agent(s).

7. Prior exposure to a BCR inhibitor (e.g., BTK, PI3K, or SYK inhibitors) or BCL-2 inhibitors (e.g., ABT-199).

8. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids for treatment of WM or other conditions. Note: Subjects may use topical or inhaled corticosteroids or low-dose steroids (≤10 mg of prednisone or equivalent per day) as therapy for comorbid conditions. During study participation, subjects may also receive systemic or enteric corticosteroids as needed for treatment-emergent comorbid conditions.

9. Grade ≥2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation.

10. Known history of HIV or active infection with HCV or hepatitis B virus (HBV) or any uncontrolled active systemic infection.

11. Major surgery within 4 weeks before first dose of study drug.

12. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.

13. History of a bleeding diathesis (e.g., hemophilia, von Willebrand disease).

14. History of stroke or intracranial hemorrhage within 6 months before the first dose of acalabrutinib.

15. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 28 days of first dose of study drug.

16. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole)

17. ANC <0.75 x 10^9/L or platelet count <50 x 10^9/L. For subjects with disease involvement in the bone marrow, ANC <0.50 x 10^9/L or platelet count <30 x10^9/L.

18. Creatinine >2.5 x institutional ULN; total bilirubin >2.5 x ULN; or AST or ALT >3.0 x ULN.

19. Lactating or pregnant.

20. Concurrent participation in another therapeutic clinical trial.

3.4.3 Replacement of Subjects

Any subject who does not complete Cycle 2 (at least 8 weeks) may be replaced at the discretion of the study investigator and sponsor.
3.4.4 Enrollment Procedures

Enrollment of a subject into the study will be performed according to the following procedures:

- Notify the sponsor when a clinically eligible subject is identified and ready to screen, to ensure enrollment availability on the study.

- After the subject has signed and dated the Informed Consent Form (ICF), all screening procedures have been completed, and eligibility has been confirmed, the subject can be officially enrolled in the study.

- To enroll a subject, the study center will fax/email a completed Enrollment Confirmation Form to the sponsor. The enrollment date will be the date that the sponsor confirms enrollment.

- The sponsor will aim to fax/email a completed Enrollment Confirmation Form to the study center within 24 hours.

Treatment must begin within the 21-day screening window (Section 4.1) and after the site has received approval from the sponsor. Study treatment is not blinded on this study.

3.5 Study Drug

3.5.1 Premedications

No specific premedications or supporting medications are required in conjunction with acalabrutinib administration.

3.5.2 Formulation, Packaging, and Storage

Acalabrutinib is manufactured according to Good Manufacturing Practices regulations and will be provided to the investigational site by Acerta Pharma or designee.

Acalabrutinib should be stored according to the instructions on the label that is affixed to the package containing the drug product. Acalabrutinib capsules contain 100 mg of drug substance. Acalabrutinib will be provided in white, high-density polyethylene bottles.

If a drug shipment arrives damaged, or if there are any other drug complaints, a Product Complaint Form should be completed and emailed or faxed to the sponsor or the sponsor’s representative. Refer to the acalabrutinib Investigator Brochure for additional information regarding the drug product to be used in this study.
3.5.3 Administration of Study Drug

Investigators are prohibited from supplying acalabrutinib to any subjects not properly enrolled in this study. The investigator must ensure that subjects receive acalabrutinib only from personnel who fully understand the procedures for administering the drug.

Acalabrutinib 100 mg (1 x 100-mg capsule) is to be administered BID, 12 hours apart (BID dosing = total daily dose of 200 mg).

Acalabrutinib is intended to be administered orally BID with 8 ounces (approximately 240 mL) of water (avoid grapefruit juice and Seville orange juice due to CYP3A inhibition). Acalabrutinib may be administered with or without food. The capsules should be swallowed intact and subjects should not attempt to open capsules or dissolve them in water.

It is recommended that acalabrutinib be taken as close to the scheduled time as possible (preferably within 1 hour). However, if a dose is missed, it can be taken up to 3 hours after the scheduled time with a return to the normal schedule for the next dose. If it has been >3 hours, the dose should not be taken and the subject should take the next dose at the next scheduled time. The missed dose will not be made up and must be returned to the site at the next scheduled visit.

3.5.4 Assuring Subject Compliance

For treatments that are taken in the clinic, subjects should take the dose from the drug dispensed for them for that particular time period. All other treatments will be taken at home. Subjects will receive a diary to record the specific time each dose was taken and to record reasons for any missed doses.

Subject compliance will be assessed at every visit. The subject will be instructed to bring the diary and any remaining capsules to the clinic at their next visit. The administrator will review the diary and ask the subject if all of the capsules were administered. Any remaining or returned capsules will be counted and recorded as described in Section 7.7. Returned capsules must not be redispensed to another subject. The study staff will resupply the subject with the correct number of capsules needed for use until the next visit.

3.5.5 Dose Delays

Treatment with acalabrutinib should be held for any unmanageable, potentially study drug-related toxicity that is Grade ≥3 in severity. Any other clinically important events
where dose delays may be considered appropriate by the investigator must be discussed with the medical monitor. Study drug may be held for a maximum of 28 consecutive days from expected dose due to toxicity. Study treatment should be discontinued in the event of a toxicity lasting >28 days, unless reviewed and approved by the medical monitor.

**Note:** Temporary withholding of study drug for as little as 7 days can cause a transient worsening of disease and/or of constitutional symptoms. Refer to Section 3.8 for more information on assessing disease progression under these circumstances.

### 3.5.6 Dose Modification and Discontinuation

The actions in Table 1 should be taken for the following toxicities:

- Grade 4 ANC (<500/μL) for >7 days (Neutrophil growth factors are permitted per American Society of Clinical Oncology guidelines [Smith 2015] and use must be recorded on the case report form [CRF]).
- Grade 3 platelet decreases in presence of significant bleeding
- Grade 4 platelet decreases
- Grade 3 or 4 nausea, vomiting, or diarrhea, if persistent despite optimal antiemetic and/or anti-diarrheal therapy
- Any other Grade 4 toxicity or unmanageable Grade 3 toxicity.

<table>
<thead>
<tr>
<th>Occurrence</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st - 2nd</td>
<td>Hold acalabrutinib until recovery to Grade ≤1 or baseline; may restart at original dose level</td>
</tr>
<tr>
<td>3rd</td>
<td>Hold acalabrutinib until recovery to Grade ≤1 or baseline; restart at 100 mg once daily</td>
</tr>
<tr>
<td>4th</td>
<td>Discontinue acalabrutinib</td>
</tr>
</tbody>
</table>

As appropriate, certain laboratory abnormalities may warrant more frequent monitoring (e.g., once per week) until abnormalities have recovered to Grade ≤1. If acalabrutinib is reduced for apparent treatment-related toxicity, the dose need not be re-escalated, even if there is minimal or no toxicity with the reduced dose. However, if the subject tolerates a reduced dose of acalabrutinib for ≥4 weeks then the dose may be increased to the next higher dose level, at the discretion of the investigator. Such re-escalation may be
particularly warranted if further evaluation reveals that the AE that led to the dose reduction was not treatment-related. However, the maximum dose of acalabrutinib is 100 mg BID for this protocol.

For full study treatment discontinuation criteria, refer to Section 3.8.

3.6 Concomitant Therapy

3.6.1 Permitted Concomitant Therapy
Antiemetics are permitted if clinically indicated. Standard supportive care medications are permitted as per institutional standards.

For subjects considered at risk for tumor lysis syndrome: Administer appropriate hydration, alkalinization of urine, and allopurinol or rasburicase per institutional standards before initiating treatment.

3.6.2 Guideline for Use of CYP Inhibiting/Inducing Drugs
At the systemic exposure levels expected in this study, acalabrutinib inhibition of CYP metabolism is not anticipated. However, as discussed in Section 1.2.7 concomitant administration of acalabrutinib with a strong or moderate CYP3A inhibitor increased exposure by approximately 5-fold. Consequently, the concomitant use of strong inhibitors/inducers of CYP3A (Appendix 3) should be avoided when possible. If a subject requires a strong or moderate CYP3A inhibitor while on study, monitor the subject closely for potential toxicities. Conversely, concomitant administration of a strong inducer of CYP3A has the potential to decrease exposure of acalabrutinib and could reduce efficacy.

3.6.3 Guideline for Use of Drugs that Affect Gastric pH
The effect of agents that reduce gastric acidity (antacids or proton-pump inhibitors) on acalabrutinib absorption was evaluated in a healthy volunteer study (ACE-HV-004). Results from this study indicate that subjects should avoid the use of calcium carbonate containing drugs or supplements for a period of at least 2 hours before and at least 2 hours after taking acalabrutinib.

Use of omeprazole, esomeprazole, lansoprazole or any other proton-pump inhibitors while taking acalabrutinib is not recommended due to a potential decrease in study drug exposure. However, the decision to treat with proton-pump inhibitors during the study is at the investigator's discretion, with an understanding of the potential benefit to the
subject’s gastrointestinal condition and a potential risk of decreased exposure to acalabrutinib.

Although the effect of H2-receptor antagonists (such as famotidine or ranitidine) on acalabrutinib absorption has not been evaluated, if treatment with an H2-receptor antagonist is required, the H2-receptor antagonist should be taken approximately 2 hours after an acalabrutinib dose.

### 3.6.4 Prohibited Concomitant Therapy

Any chemotherapy, immunotherapy, kinase inhibitors, bone marrow transplantation, experimental therapy, and radiotherapy are prohibited. High-dose corticosteroids used to treat underlying WM are not allowed on study.

Localized, short courses of radiotherapy are allowed for the treatment of lesions unrelated to the disease under study, if approved by the medical monitor.

Warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) are prohibited.

### 3.7 Risks Associated with Acalabrutinib Treatment

The following summarizes the experience with acalabrutinib in hematological cancer studies. Full details regarding the clinical safety of acalabrutinib are presented in the acalabrutinib Investigator Brochure.

#### 3.7.1 Hemorrhage

Bleeding events, some fatal, including central nervous system, respiratory, and gastrointestinal hemorrhage, have been reported in patients treated with acalabrutinib.

Subjects receiving antiplatelet or anticoagulant therapies may be at increased risk of hemorrhage and should be monitored for signs of bleeding. As a precaution, it is suggested per protocol that acalabrutinib be withheld for at least 3 days pre- and post-surgery.

Subjects with hemorrhage should be managed per institutional guidelines or as clinically indicated.

#### 3.7.2 Infections

Serious infections, including fatal events, have been reported in patients treated with acalabrutinib. Subjects should be monitored for signs and symptoms of infection and treated as medically appropriate.
3.7.2.1 Progressive Multifocal Leukoencephalopathy

Cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with acalabrutinib. Signs and symptoms of PML may include cognitive and behavioral changes, language disturbances, visual disturbances, sensory deficits, weakness, and coordination and gait difficulties.

If PML is suspected, hold further treatment with acalabrutinib treatment until PML is excluded. A diagnostic evaluation may include (but is not limited to):

- Neurologic consultation
- Brain magnetic resonance imaging (MRI)
- Polymerase chain reaction (PCR) analysis for John Cunningham virus DNA in cerebrospinal fluid

If PML is confirmed, permanently discontinue acalabrutinib.

3.7.2.2 Hepatitis B Virus Reactivation

Serious or life-threatening reactivation of viral hepatitis may occur in subjects treated with a BTK inhibitor (de Jésus Ngoma 2015). Cases of HBV reactivation have been reported in patients treated with acalabrutinib with 1 case resulting in liver failure and death. Therefore, subjects with a history of HBV infection should be monitored monthly with a quantitative PCR test for HBV DNA from Cycle 6 to Cycle 48 or early discontinuation, and then every 3 months thereafter. Monitoring should continue until 12 months after last dose of acalabrutinib. Any subject with a rising viral load (above lower limit of detection) should discontinue study drug and have antiviral therapy instituted and a consultation with a physician with expertise in managing hepatitis B. Insufficient data exist regarding the safety of resuming acalabrutinib in subjects who develop HBV reactivation.

3.7.3 Cytopenia

Grade 3 or 4 events of cytopenia, including neutropenia, anemia, and thrombocytopenia have occurred in patients treated with acalabrutinib. Monitor blood counts as specified in the schedule of assessments and as medically appropriate. Refer to Section 3.5.6 for study drug modification guidance. Subjects with cytopenia should be managed according to institutional guidelines or as clinically indicated.

3.7.4 Second Primary Malignancies

Second primary malignancies, including non-skin carcinomas, have been reported in patients treated with acalabrutinib. The most frequent second primary malignancy was
skin cancer (squamous cell carcinoma of the skin). Subjects with a second primary malignancy should be managed according to institutional guidelines or as clinically indicated.

3.7.5 Atrial Fibrillation

Atrial fibrillation or flutter has been reported in patients treated with acalabrutinib. Risk factors may include hypertension, diabetes mellitus, acute infections, or a previous history of atrial fibrillation. Subjects with atrial fibrillation should be managed per institutional guidelines or as clinically indicated.

3.7.6 Dietary Restrictions

Because acalabrutinib is metabolized by CYP3A (see Section 1.2.7), subjects should be strongly cautioned against excessive consumption of grapefruit, grapefruit juice, Seville oranges, or Seville orange juice (which contain potent CYP3A inhibitors) or using herbal remedies or dietary supplements (in particular, St. John’s wort, which is a potent CYP3A4 inducer). Acalabrutinib can be taken with or without food.

Otherwise, subjects should maintain a normal diet unless modifications are required to manage an AE such as diarrhea, nausea, or vomiting.

3.7.7 Reproductive Toxicity

Developmental and reproductive toxicology studies in rats have not identified acalabrutinib-related toxicities for fertility, reproductive success, embryofetal development or embryofetal survival. In rabbits, at dose levels which resulted in maternal toxicities, skeletal variations were associated with reductions in fetal weights. For additional details, refer to the acalabrutinib Investigator Brochure.

Definition of women of non-reproductive potential:

Women will be considered of non-reproductive potential if they are either:

1) Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women <45 years of age a high follicle stimulating hormone level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single follicle stimulating hormone measurement is insufficient.);

OR
2) Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks before screening;

OR

3) Have a congenital or acquired condition that prevents childbearing.

Definition of highly effective methods of contraception:

Highly effective methods of contraception (to be used during heterosexual activity) are defined as methods that can achieve a failure rate of <1% per year when used consistently and correctly. Such methods include:

- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal, or transdermal
- Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable
- Intrauterine device or intrauterine hormone-releasing system
- Bilateral tubal occlusion
- Vasectomy of a female subject's male partner (with medical assessment and confirmation of vasectomy surgical success)
- Sexual abstinence (only if refraining from heterosexual intercourse during the entire period of risk associated with the study treatments)

Hormonal contraception may be susceptible to interaction with study or other drugs, which may reduce the efficacy of the contraception method.

Abstinence (relative to heterosexual activity) can only be used as the sole method of contraception if it is consistently employed during the entire period of risk associated with the study treatments as the subject’s preferred and usual lifestyle. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, and postovulation methods) and withdrawal are not acceptable methods of contraception.

If a contraceptive method is restricted by local regulations/guidelines, then it does not qualify as an acceptable highly effective method of contraception for subjects participating at sites in the relevant country/region.

Female subjects with reproductive potential (see definition above) who are sexually active must use highly effective methods of contraception during the study and for 2 days after the last dose of acalabrutinib. If there is any question that a subject of childbearing potential will not reliably comply with the requirements for contraception, that subject should not be entered into the study.
Subjects should promptly notify the investigator if they, or their partners, become pregnant during this study. Female subjects must also notify the investigator if they become pregnant within 2 days after the last dose of acalabrutinib. If a woman becomes pregnant during the treatment period, she must discontinue acalabrutinib immediately. Pregnancy in a female subject or a male subject’s partner must be reported as outlined in Section 6.2.3.

3.7.8 Overdose Instructions

For any subject experiencing an acalabrutinib overdose (ingestion of more than the recommended dosage), observation for any symptomatic side effects should be instituted, and vital signs and biochemical and hematologic parameters should be followed closely (consistent with the protocol or more frequently, as needed). Appropriate supportive management to mitigate adverse effects should be initiated. If the overdose ingestion is recent and substantial, and if there are no medical contraindications, use of gastric lavage or induction of emesis may be considered.

The medical monitor should be contacted if an acalabrutinib overdose occurs.

3.8 Withdrawal of Subjects from Study Treatment

The investigator, in consultation with the medical monitor, may withdraw any subject from study treatment, if, in the investigator’s opinion, it is not in the subject’s best interest to continue.

Any subject has the right to withdraw from the study at any time. In addition, subjects may be withdrawn from study treatment for the following reasons:

- Study treatment should be discontinued in the event of a toxicity requiring a dose hold lasting >28 days, unless reviewed and approved by the medical monitor.

- Any subject who has confirmed objective evidence of cancer progression while receiving acalabrutinib should be withdrawn from the study treatment. If there is uncertainty regarding whether there is true cancer progression, the subject may continue study treatment and remain under close observation (e.g., evaluated at 4-week intervals) pending confirmation of progression. In particular, transient worsening of disease early in therapy or during temporary interruption of study therapy (e.g., for drug-related toxicity, surgery, or intercurrent illness) may not indicate cancer progression. In such circumstances, and if medically appropriate, subjects may resume therapy and relevant clinical, laboratory,
and/or radiologic assessment can be attempted to document whether tumor control can be maintained or whether cancer progression has occurred.

- Any subject whose medical condition substantially changes after entering the study should be carefully evaluated by the investigator in consultation with the medical monitor. Such subjects should be withdrawn from study treatment if continuing would place them at risk.

- Any subject who becomes pregnant should be removed from study treatment.

- Any subject who becomes significantly noncompliant with study drug administration, study procedures, or study requirements should be withdrawn from study treatment in circumstances that increase risk or substantially compromise the interpretation of study results.

3.9 Reasons for Study Exit
Reasons for study exit include:

- Subject’s withdrawal of consent from study
- Decision by sponsor to terminate the study
- Subject lost to follow-up
- Death

3.10 Data and Safety Monitoring
This study will be monitored in accordance with the sponsor’s pharmacovigilance procedures. AEs and SAEs will be reviewed internally on an ongoing basis to identify safety concerns. Conference calls with the investigators will be conducted as needed to discuss study progress, obtain investigator feedback and exchange, and discuss "significant safety events" (i.e., AEs that led to dose modifications, treatment-related SAEs, and deaths).

4.0 STUDY ACTIVITIES AND ASSESSMENTS
The schedule of events is provided in Appendix 4. Descriptions of the scheduled evaluations are outlined below and complete information on study drug and dosing is provided in Section 3.5.

Before study entry, throughout the study, and at the follow-up evaluation, various clinical and diagnostic laboratory evaluations are required. The purpose of obtaining these detailed measurements is to ensure adequate safety and tolerability assessments.
Clinical evaluations and laboratory studies may be repeated more frequently if clinically indicated. Such unscheduled assessments will be captured in the protocol-specific database as appropriate. This study will primarily use central laboratory testing for laboratory evaluations. Samples from sites' local laboratories may be used if central testing is unavailable.

4.1 Description of Procedures

4.1.1 Informed Consent
The subject must read, understand, and sign the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF confirming his or her willingness to participate in this study before initiating any screening activity that is not considered standard of care by institutional standards. Subjects must also grant permission to use protected health information.

4.1.2 Medical History
Collect and record the subject's complete history through review of medical records and by interview. Concurrent medical signs and symptoms must be documented to establish baseline severities. A disease history, including the date of initial diagnosis and list of all prior anticancer treatments, and responses and duration of responses to these treatments, also will be recorded.

4.1.3 Adverse Events
The accepted regulatory definition for an AE is provided in Section 6.1. The AE reporting period is described in Section 6.2.1. Important additional requirements for reporting SAEs are explained in Section 6.1.5.

4.1.4 Concomitant Medications and Therapy
Document all concomitant medications and procedures from within 21 days before the start of study drug administration through 30 days after the last dose of study drug.

4.1.5 Confirmation of Eligibility
Subject eligibility for enrollment will be assessed per Section 3.4. All screening procedures, unless otherwise indicated, should be completed within 21 days of the first dose of study drug.

4.1.6 ECOG Performance Status
The ECOG performance index is provided in Appendix 1.
4.1.7 Physical Examination, Vital Signs, Height & Weight
The screening physical examination will include, at a minimum, the general appearance of the subject, height (screening only) and weight, and examination of the skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, nervous system, and lymphatic system. The nervous system examination will include attention to neurologic signs and symptoms of PML.

Symptom-directed physical examinations, including extramedullary disease assessments by palpation, will be done during the treatment period and at the SFU visits.

Vital signs (blood pressure, heart rate, respiratory rate, and body temperature) will be assessed after the subject has rested in the sitting position.

4.1.8 Patient-Reported Outcomes
A health-related quality of life questionnaire will be administered to each subject as outlined in the schedule of assessments. Refer the PRO manual for this study for instructions on administering this questionnaire.

4.1.9 Bone Marrow Aspirate and Biopsy
A bone marrow aspirate and biopsy will be done at screening or up to 60 days before the first dose of study drug. This study requires a bone marrow aspirate and biopsy at the end of Cycle 2 and Cycle 12, which must be done within 4 weeks of the contemporaneous radiologic evaluation. Per the current response criteria (Owen 2013), a bone marrow aspirate and biopsy will also be required at any time on study to confirm a complete response (CR). Pathologic review of the bone marrow aspirate and biopsy will be performed by a central laboratory (or local laboratory, if central laboratory is unavailable) for confirmation of WM diagnosis.

When available, any unused bone marrow tissue will be used for PD testing. PD testing will be done by the sponsor.

4.1.10 Electrocardiogram
Subjects should be in supine position and resting for ≥10 minutes before study-related ECGs.
4.1.11 Urine or Serum Pregnancy Test
Pregnancy tests will be required only for women of childbearing potential. Testing will be done locally by use of central laboratory provided kits. Pregnancy testing may be done by local laboratories and can be done more frequently than the protocol-defined schedule, if required by local regulatory authorities.

4.1.12 Hematology
Hematology studies must include complete blood count with differential and platelet and reticulocyte counts. Testing will be done by the central laboratory.

4.1.13 Serum Chemistry
Serum chemistry must include albumin, alkaline phosphatase, ALT, AST, bicarbonate, blood urea nitrogen, bone-specific alkaline phosphatase, calcium, chloride, creatinine, c-terminal telopeptide, glucose, lactate dehydrogenase, magnesium, phosphate, potassium, sodium, total bilirubin, total protein, and uric acid. If an unscheduled ECG is done at any time, then an electrolyte panel (i.e., calcium, magnesium, and potassium) must be done to coincide with the ECG testing. Testing will be done by the central laboratory.

See Appendix 5 for actions required in cases of increases in liver biochemistry and evaluation of Hy’s law.

4.1.14 Urinalysis
Urinalysis includes pH, ketones, specific gravity, bilirubin, protein, blood, and glucose. Testing will be done by the central laboratory.

4.1.15 T/B/NK Cell Count
Flow cytometry testing will include CD3+, CD4+, CD8+, CD19+, and CD16/56+ cells. Testing will be done by the central laboratory.

4.1.16 Serum Immunoglobulin and Serum M protein
Testing for IgG, IgM, IgA, and serum M protein levels (by SPEP and IFE) will be done by the central laboratory.

4.1.17 HBV PCR Testing
Refer to Section 3.7.2.2 and Appendix 4 for information on the required HBV PCR testing for subjects with a history of HBV infection.
4.1.18 Pharmacodynamics
PD assessments will be done on all subjects in the treatment-naive cohort and on up to 12 subjects in the previously treated cohort. Blood samples and bone marrow, when available, will be used for PD testing (e.g., BTK occupancy and B-cell activation). Refer to the laboratory binder for instructions on collecting and processing these samples. Testing will be done by the sponsor.

4.1.19 Pharmacokinetics
PK assessments will be done on all subjects in the treatment-naive cohort and on up to 12 subjects in the previously treated cohort. Refer to the laboratory binder for instructions on collecting and processing these samples. Testing will be performed at the central clinical laboratory. Leftover plasma samples may be used for exploratory acalabrutinib metabolite analyses. The PK sampling timepoints are provided in Table 2.

Table 2. Pharmacokinetic Sample Schedule

<table>
<thead>
<tr>
<th>Cycle</th>
<th>Day</th>
<th>Predose</th>
<th>0.5 (±5 min)</th>
<th>0.75 (±5 min)</th>
<th>1 (±5 min)</th>
<th>2 (±10 min)</th>
<th>4 (±10 min)</th>
<th>6 (±10 min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>8</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15, 22, 28</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All timepoints are relative to the morning dose.

4.1.20 Molecular Testing
Molecular testing will include, but may not be limited to, immunoglobulin heavy-chain variable mutational status, CXCR4<sup>S338X</sup>, and MYD88 L265P. Molecular testing may be performed using the blood samples collected for PD testing (when available), as a separate sample was not collected at screening.

4.1.21 Extramedullary Disease Assessment
Pretreatment radiologic extramedullary disease assessment will be performed within 30 days before the first dose. A computed tomography (CT) scan with contrast (unless contraindicated) of the chest, abdomen, and pelvis and any other disease sites (e.g., neck) are required for the pretreatment extramedullary disease assessment for all subjects.
On-study extramedullary disease assessments will also be done by physical examination and laboratory results. Bone marrow and radiologic (as applicable) assessments are required for confirmation of CR per clinical guidelines (see Section 4.2). De-identified copies of all radiology results may be requested by the sponsor.

For subjects with baseline (screening) extramedullary disease, follow-up radiologic assessments are required at the end of Cycle 2 (±7 days), Cycle 4 (±7 days), and Cycle 6 (±7 days), then every 3 cycles (12 weeks, ±7 days) until Cycle 27, and then every 6 cycles thereafter or more frequently at investigator discretion. Subjects should have radiologic extramedullary disease measurements done at the participating study center or an acceptable alternate imaging facility using an identical imaging protocol and similar equipment. The same imaging equipment should be used for all scans whenever possible. The same radiologist should be assigned to read all the scans for a given subject throughout the study. MRI may be used to evaluate non-target lesions that cannot be adequately imaged using CT (in cases where MRI is desirable, the MRI must be obtained at baseline and at all subsequent response evaluations). If MRI is required for any other reason, this must be discussed with the study medical monitor first.

Up to 6 measurable lymph nodes (only target lesions >1.5 cm in the longest diameter may be assessed), clearly measurable in 2 perpendicular dimensions, will be followed as target lesions for each subject. Measurable sites of disease should be chosen such that they are representative of the subject’s disease. In addition, selection of target lesions should be from as disparate regions of the body as possible when these areas are significantly involved. If additional lesions are present but are not included in the target lesion assessment, they can be added as non-target lesions followed throughout the study. The cranial-caudal measurement of the spleen and longest diameter of the liver will be assessed at screening and all subsequent response evaluations.

In the event disease progression is suspected in subjects with baseline extramedullary disease, a CT scan must be performed. If the sole lesion lies within the field of prior radiotherapy, there must be evidence of disease progression in that lesion.

4.1.22 Study Drug Accountability

See Section 7.7.
4.1.23 Routine Clinical Assessments

Routine clinical assessments include physical examinations, recording of symptoms, and hematologic evaluations to evaluate for both AEs and assessment of disease progression at times when the CT scan is not obtained. If a subject shows signs of progression, the subject may continue treatment until progression is considered unequivocal progression by the investigator. The investigator should report any suspected disease progression to the sponsor or designee. Subjects should continue to be followed and adhere to study-related procedures regardless of the administration of subsequent anticancer therapy.

4.2 Investigator’s Assessment of Response to Treatment

The investigator must rate the subject’s response to treatment per the Owen criteria (Owen 2013) and modified 3rd IWWM workshop criteria (Kimby 2006); see Table 3 and Table 5. Progression will be assessed by the Owen criteria (Owen 2013) and modified 3rd IWWM workshop criteria (Kimby 2006); see Table 4 and Table 6.

Overall response assessments will include evaluation of physical examinations, recording of symptoms, laboratory evaluations (Note: Serum immunoglobulins and serum M protein must be done within 7 days and bone marrow aspirate and biopsy [when applicable] must be done within 4 weeks of the contemporaneous radiologic evaluation), and radiologic evaluations per the schedule of assessments. Subjects who have signs and symptoms of progression outside of the scheduled assessment should be evaluated by the investigator with a physical examination and serum immunoglobulins and serum M protein to determine if disease progression is present. Additionally, any suspected case of disease progression should be assessed with a CT scan for subjects with baseline extramedullary disease, and should be reported to the medical monitor. Subjects may continue study treatment until progression is confirmed by a serial examination (e.g., physical examination, serum immunoglobulins and serum M protein, or CT scan) at least 2 weeks later.
### Table 3. Response Assessment Criteria for Waldenström Macroglobulinemia (Owen 2013)

<table>
<thead>
<tr>
<th>Response</th>
<th>Definition</th>
</tr>
</thead>
</table>
| Complete response            | • Absence of serum monoclonal IgM protein by immunofixation  
                               | • Normal serum IgM level  
                               | • Complete resolution of extramedullary disease, i.e., lymphadenopathy and splenomegaly if present at baseline  
                               | • Morphologically normal bone marrow aspirate and trephine biopsy  |
| Very good partial response   | • Monoclonal IgM protein is detectable  
                               | • ≥90% reduction in serum IgM level from baseline<sup>a</sup>  
                               | • Complete resolution of extramedullary disease, i.e., lymphadenopathy/splenomegaly if present at baseline  
                               | • No new signs or symptoms of active disease  |
| Partial response             | • Monoclonal IgM protein is detectable  
                               | • ≥50% but <90% reduction in serum monoclonal IgM level from baseline<sup>a</sup>  
                               | • Reduction in extramedullary disease i.e., lymphadenopathy/splenomegaly if present at baseline  
                               | • No new signs or symptoms of active disease  |
| Minor response               | • Monoclonal IgM protein is detectable  
                               | • ≥25% but <50% reduction in serum monoclonal IgM level from baseline<sup>a</sup>  
                               | • No new signs or symptoms of active disease  |
| Stable Disease               | • Monoclonal IgM protein is detectable  
                               | • <25% reduction and <25% increase in serum monoclonal IgM level from baseline<sup>a</sup>  
                               | • No progression in extramedullary disease i.e., lymphadenopathy/splenomegaly  
                               | • No new signs or symptoms of active disease  |

IgM=immunoglobin M  
<sup>a</sup> Sequential changes in IgM levels may be determined either by M protein quantitation or total serum IgM quantitation by nephelometry.

### Table 4. Progressive Disease Criteria for Waldenström Macroglobulinemia (Owen 2013)

<table>
<thead>
<tr>
<th>Definition</th>
</tr>
</thead>
</table>
| • ≥25% increase in serum IgM level<sup>a</sup> with an absolute increase of at least 500 mg/dL from lowest nadir (requires confirmation on ≥2 consecutive measurements at least 4 weeks apart).  
                               | AND/OR  
                               | • Progression of clinical features attributable to the disease per Owen 2013.  |

IgM=immunoglobin M  
<sup>a</sup> Sequential changes in IgM levels may be determined either by M protein quantitation or total serum IgM quantitation by nephelometry.
Table 5. Response Assessment for Waldenström Macroglobulinemia (Modified 3rd IWWM Workshop Criteria; Kimby 2006)

<table>
<thead>
<tr>
<th>Response</th>
<th>Definition</th>
</tr>
</thead>
</table>
| Complete response       | • Resolution of all symptoms  
                          | • Normalization of serum IgM  
                          | • Complete disappearance of IgM paraprotein by immunofixation  
                          | • Resolution of any adenopathy or splenomegaly                      |
| Very good partial       | • ≥90% reduction in serum IgM level from baseline                           |
| response                |                                                                              |
| Partial response        | • ≥50% but <90% reduction in serum monoclonal IgM level from baselinea       |
| Minor response          | • ≥25% but <50% reduction in serum monoclonal IgM level from baselinea       |
| Stable Disease          | • <25% reduction and <25% increase in serum monoclonal IgM level from baselinea  
                          | • Absence of new or increasing adenopathy or splenomegaly and/or other progressive signs or symptoms of WM. |

IgM=immunoglobin M  
a Sequential changes in IgM levels may be determined either by M protein quantitation or total serum IgM quantitation by nephelometry.

Table 6. Progressive Disease Criteria for Waldenström Macroglobulinemia (Modified 3rd IWWM Workshop Criteria; Kimby 2006)

<table>
<thead>
<tr>
<th>Definition</th>
</tr>
</thead>
</table>
| • ≥25% increase in serum IgM level with an absolute increase of at least 500 mg/dL from lowest attained response value. Reconfirmation of the initial IgM increase is required when IgM is the sole criterion for progressive disease confirmation AND/OR  
                          | • Progression of clinically significant disease-related symptom(s) AND/OR  
                          | • Death from any cause or initiation of a new anti-neoplastic therapy will also be considered a progression event. |

IgM=immunoglobin M

4.3 Treatment Termination and Safety Follow-Up Visits

A TT visit is required for safety assessments for any subjects who permanently discontinue study drug for any reason (except for death, loss to follow-up, or withdrawal of consent), including disease progression. The TT visit should be scheduled within 7 days of the last dose of study drug, if possible, and is not required for subjects who discontinue from study treatment within 10 days after a scheduled study visit.

In addition to the TT visit, each subject should be followed for SFU visit 30 days after his or her last dose of study drug to monitor for resolution or progression of AEs and to document the occurrence of any new events, regardless of whether the subject receives
a new anticancer therapy or demonstrates disease progression within this timeframe. Subjects who withdraw consent for study treatment should still be encouraged to complete the SFU assessments before withdrawing consent, but these assessments cannot be mandated if subject consent for further study participation is withdrawn. If the TT visit and the SFU visit coincide, then these can be combined into 1 visit. The Schedule of Assessments (Appendix 4) describes the procedures required for the TT and SFU visits.

4.4 Follow-Up for Progression and Survival

Follow-Up after Study Treatment Discontinuation

Subjects who discontinue study treatment for reasons other than progressive disease (including subjects who discontinued due to AE and start use of alternative anticancer therapy) will be followed approximately every 3 months until disease progression. During this period, for subjects who require scans, the scans will be done every 3 months until 2 years, and then every 6 months thereafter until progression. Additionally, serum IgM and physical examinations will be collected every 6 months. Refer to Appendix 4 for the full list of assessments required during this period.

Long-Term Follow-Up

Once subjects progress—for all subjects who have not withdrawn consent—they will be contacted approximately every 3 months by clinic visit or telephone, to assess survival and the use of alternative anticancer therapy until death or loss to follow-up.

4.5 Missed Evaluations

Missed evaluations should be rescheduled and performed as close to the original scheduled date as possible. An exception is made when rescheduling becomes, in the investigator’s opinion, medically unnecessary or unsafe because it is too close in time to the next scheduled evaluation. In that case, the missed evaluation should be abandoned.

5.0 STATISTICAL METHODS OF ANALYSIS

5.1 General Considerations

Descriptive statistics (including means, standard deviations, and medians for continuous variables and proportions for discrete variables) will be used to summarize data as appropriate.
5.2 Sample Size Considerations

Previously treated subjects: Simon’s optimal 2-stage design

Response includes CR, very good partial response (VGPR), PR, or MR as defined in Section 5.5.3. This study will test the null hypothesis that the ORR is ≤35% against the alternative hypothesis that it is ≥55%. Using Simon’s optimal 2-stage design, a total sample size of 76 subjects has 90% power to achieve a 1-sided significance level of 0.025. In Stage 1, 28 subjects will be evaluated for efficacy. If ≥12 out of 28 subjects (43%) achieve a response, then the study will continue to full enrollment. In Stage 2, a further 48 subjects will be enrolled. With Simon's optimal 2-stage design, an ORR of ≥46% (i.e., ≥35 subjects responding out of 76 subjects evaluated) will achieve a 1-sided significance level of ≤0.025.

Treatment-naive subjects: Exploratory cohort

No formal statistical tests of hypotheses will be performed. Eight to 12 evaluable subjects will be enrolled in this cohort for evaluation of preliminary efficacy and safety in this patient population.

5.3 Definition of Analysis Populations

The analysis population is defined as follows:

**All-Treated Population:** All enrolled subjects who receive ≥1 dose of study drug. The safety analyses and primary efficacy analyses will be performed on the All-treated population.

**Efficacy-evaluable population:** All subjects in the All-treated population who have ≥ 1 evaluable response assessment after the first dose of study drug. Sensitivity analyses for efficacy will be carried out on the efficacy-evaluable population.

5.4 Missing Data Handling

No imputation of values for missing data will be performed except for missing or partial start and end dates for AEs and concomitant medications according to prespecified, conservative imputation rules.

5.5 Endpoint Data Analysis

5.5.1 Safety Analysis

Safety summaries will be included in the form of tables and listings. The frequency (number and percentage) of treatment-emergent AEs will be mapped using MedDRA...
and reported in each treatment group by MedDRA System Organ Class and Preferred Term. Summaries will also be presented by the severity of the AE (per CTCAE, v4.03 or higher) and by relationship to study drug. SAEs and AEs leading to study drug discontinuation will be summarized.

Laboratory shift tables containing counts and percentages will be presented by laboratory parameter and time. Figures of changes in selected laboratory parameters over time will be generated.

Results of vital sign assessments and physical examinations will be tabulated and summarized.

Figures of change from baseline will be generated to assess effect of acalabrutinib on peripheral T/B/NK cell counts and on serum immunoglobulin levels.

5.5.2 Demographics and Baseline Characteristics
Additional analyses will include summaries of subject demographics, baseline characteristics, and concurrent treatments. Concomitant medications will be coded according to the World Health Organization Drug Dictionary and tabulated.

5.5.3 Analysis of Efficacy Parameters
Efficacy parameters will be based on investigator assessment according to the response assessment criteria for WM (Owen 2013) and the modified 3rd IWWM workshop criteria (Kimby 2006). Efficacy parameters will be analyzed by the investigator. The co-primary endpoints are ORRs, defined as a subject achieving a MR or better according to the response assessment criteria for WM (Owen 2013) and by the modified 3rd IWWM workshop criteria (Kimby 2006), both as assessed by the investigator.

Overall Response Rate
ORR is defined as the proportion of subjects who achieve a CR, VGPR, PR, or MR. ORR will be calculated and the corresponding 95% 2-sided confidence interval will be derived.

Duration of Response
DOR is defined as the interval from the first documentation of CR, VGPR, PR, or MR to the earlier of the first documentation of definitive disease progression or death from any cause. Kaplan-Meier methods will be used to estimate event-free curves and corresponding quartiles (including the median). Data from surviving, non-progressing
subjects will be censored at the earliest of the time of initiation of anticancer treatment or the last time that lack of WM progression was documented.

**Progression-free Survival**

PFS is defined as the interval from the start of acalabrutinib therapy to the earliest documentation of disease progression (per Table 4) or death from any cause. Kaplan-Meier methods will be used to estimate the event-free curves and corresponding quartiles (including the median). Data from surviving, non-progressing subjects will be censored at the earliest of the time of initiation of anticancer treatment or the last time that lack of disease progression was documented.

**Overall Survival**

The duration of OS will be measured from the start of acalabrutinib therapy until the date of death. Subjects who are known to be alive as of their last known status will be censored at their date of last contact. Kaplan-Meier methodology will be used to estimate overall survival curves and corresponding quartiles (including the median).

### 5.5.4 Analysis of Pharmacokinetic/Pharmacodynamic Parameters

The plasma PK of acalabrutinib will be characterized using noncompartmental analysis. The following PK parameters will be calculated, whenever possible, from plasma concentrations of acalabrutinib:

- **AUC\(_{0\text{-last}}\)** Area under the plasma concentration-time curve calculated using linear trapezoidal summation from time 0 to time last, where “last” is the time of the last measurable Ct.
- **AUC\(_{0\text{-12}}\)** Area under the plasma concentration-time curve from 0 to 12 hours, calculated using linear trapezoidal summation.
- **AUC\(_{0\text{-inf}}\)** Area under the plasma concentration-time curve from 0 to infinity, calculated using the formula: \(AUC_{0\text{-inf}} = AUC_{0\text{-last}} + \frac{Ct}{\lambda_z}\), where \(\lambda_z\) is the apparent terminal elimination rate constant.
- **AUC\(_{0\text{-24calc}}\)** Area under the plasma concentration-time curve from 0 to 24 hours, calculated by doubling the value for AUC\(_{0\text{-12}}\).
- **C\(_{\text{max}}\)** Maximum observed plasma concentration
- **T\(_{\text{max}}\)** Time of the maximum plasma concentration (obtained without interpolation)
• $t_{\frac{1}{2}}$ Terminal elimination half-life (whenever possible)
• $\lambda_z$ Terminal elimination rate constant (whenever possible)
• CL/F Oral clearance
• Vz/F Oral volume of distribution

Missing dates or times may be imputed for PK and PD samples if the missing values can be established with an acceptable level of accuracy based on other information obtained during the visit in question. If PK and PD sampling for a given subject is not performed according to protocol instructions, the subject may be excluded from the PK and PD analyses.

The PK parameters will be tabulated and summarized using descriptive statistics.

For each PD variable, the change from baseline to each assessment will be summarized. As appropriate, the on-treatment values will be compared with the pretreatment baseline values using paired t-tests. Acalabrutinib concentration-effect relationships will be explored.

5.5.5 Explorative or Correlative Analyses

Additional PK or PD analyses may be performed, as deemed appropriate.

Correlations between subject characteristics and outcome measures and correlations among outcomes measures may be explored using regression models or other appropriate techniques.

5.5.6 Patient-Reported Outcome

The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-30 will be used to assess health-related quality of life. The instrument will be scored, missing values handled, and standardized scores derived (ranging from 0–100) as recommended in the EORTC user manual. At each assessment point, absolute scores and changes from baseline will be calculated for each subscale, including core and overall total score. Tables and graphs will be generated to summarize the absolute scores and changes from baseline.

5.6 Interim Analysis

One formal interim analysis for futility with respect to ORR will be performed and documented. The formal documentation of the interim analysis will occur when subjects in Stage 1 (28 subjects) have been enrolled and have 8 weeks of evaluable response
data for efficacy. However, should at any time ≥12 responses (MR or better) be observed among the 28 subjects enrolled, Stage 2 enrollment will continue without hold. Further enrollment of subjects into Stage 2 will be halted if there are <12 responders (MR+PR+VGPR+CR) observed among these 28 subjects. If there are at least 12 responders at the time the twenty-eighth subject has enrolled, screening for and enrollment into Stage 2 will not be halted as the minimum criteria for continuing enrollment will have been met.

In The Netherlands and France, enrollment in the exploratory cohort of subjects with treatment-naive WM will commence after efficacy has been confirmed in Stage 1 of the Simon’s optimal 2-stage design.

5.7 Primary and Final Analysis
The primary analysis will occur when all subjects have completed Cycle 27 or have discontinued before Cycle 27. A final analysis will be performed at end of study. End of study is defined as the time when the last subject completes his or her last visit.

6.0 ASSESSMENT OF SAFETY
Safety assessments will consist of monitoring and recording AEs and SAEs; measurements of protocol-specified hematology, clinical chemistry, urinalysis, and other laboratory variables; measurement of protocol-specified vital signs; and other protocol-specified tests that are deemed critical to the safety evaluation of the study drug.

6.1 Definitions

6.1.1 Adverse Events
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational (medicinal) product, regardless of attribution.

This includes the following:

- AEs not previously observed in the subject that emerge during the protocol-specified AE reporting period, including signs or symptoms associated
with WM that were not present before the AE reporting period (see Section 6.2.1).

- Pre-existing medical conditions (other than the condition being studied) judged by the investigator to have worsened in severity or frequency or changed in character during the protocol-specified AE reporting period.
- Abnormal laboratory values considered clinically significant by the investigator should be reported as an AE.

The following are NOT considered an AE:

- **Pre-existing condition that has not worsened**: A pre-existing condition (documented on the medical history CRF) is not considered an AE unless the severity, frequency, or character of the event worsens during the study period.
- **Preplanned hospitalization**: A hospitalization planned before signing the ICF is not considered an SAE, but rather a therapeutic intervention. However, if during the preplanned hospitalization an event occurs, which prolongs the hospitalization or meets any other SAE criteria, the event will be considered an SAE. Surgeries or interventions that were under consideration, but not performed before signing the ICF, will not be considered serious if they are performed after signing the ICF for a condition that has not changed from its baseline level. Elective hospitalizations for social reasons, solely for the administration of chemotherapy, or due to long travel distances are also not SAEs.
- **Diagnostic testing and procedures**: Testing and procedures should not be reported as AEs or SAEs, but rather the cause for the test or procedure should be reported. If a test or procedure is done to rule out a diagnosis, the sign or symptom leading to the test/procedure should be the event term, and the event term should only be updated to the diagnosis if/when the diagnosis is confirmed. Testing and procedures performed solely as screening measures (e.g., routine screening mammography or colonoscopy) should not be reported as AEs or SAEs.
- **Abnormal laboratory results that the investigator considers to not be clinically significant**: Abnormal laboratory results are not AEs unless they are clinically significant. For example, a clinically significant laboratory result is one that requires treatment (for example a blood transfusion for low hemoglobin) or
requires a change in study drug (e.g., lowering the dose or withholding study drug while the laboratory finding resolves or stabilizes).

6.1.2 Serious Adverse Event

The terms “severe” and “serious” are not synonymous. Severity (or intensity) refers to the grade of an AE (see below). “Serious” is a regulatory definition and is based on subject or event outcome or action criteria usually associated with events that pose a threat to a subject’s life or functioning. Seriousness (not severity) serves as the guide for defining regulatory reporting obligations from the sponsor to applicable regulatory authorities.

An AE should be classified as an SAE if it meets any 1 of the following criteria:

- It results in death (i.e., the AE actually causes or leads to death).
- It is life-threatening (i.e., the AE, in the view of the investigator, places the subject at immediate risk of death. It does not include an AE that, had it occurred in a more severe form, might have caused death).
- It requires or prolongs in-patient hospitalization.
- It results in persistent or significant disability/incapacity (i.e., the AE results in substantial disruption of the subject’s ability to conduct normal life functions).
- It results in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product.
- It is considered a significant medical event by the investigator based on medical judgment (e.g., may jeopardize the subject or may require medical/surgical intervention to prevent 1 of the outcomes listed above).

6.1.3 Adverse Events of Special Interest

The following events are AEs of special interest (AESIs) for subjects who receive acalabrutinib and must be reported to the sponsor expeditiously (see Section 6.2.4 for reporting instructions), irrespective of regulatory seriousness criteria or causality:

- Ventricular arrhythmias (e.g., ventricular extrasystoles, ventricular tachycardia, ventricular arrhythmia, ventricular fibrillation, etc.)
6.1.4 Severity

Definitions found in the CTCAE version 4.03 or higher will be used for grading the severity (intensity) of AEs. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each referenced AE. Should a subject experience any AE not listed in the CTCAE, the following grading system should be used to assess severity:

- Grade 1 (Mild AE) – experiences which are usually transient, requiring no special treatment, and not interfering with the subject’s daily activities
- Grade 2 (Moderate AE) – experiences which introduce some level of inconvenience or concern to the subject, and which may interfere with daily activities, but are usually ameliorated by simple therapeutic measures
- Grade 3 (Severe AE) – experiences which are unacceptable or intolerable, significantly interrupt the subject’s usual daily activities, and require systemic drug therapy or other treatment
- Grade 4 (Life-threatening or disabling AE) – experiences which cause the subject to be in imminent danger of death
- Grade 5 (Death related to AE) – experiences which result in subject death

6.1.5 Adverse Drug Reactions

For the purpose of reporting AEs and SAEs, see Section 6 of the Investigator Brochure, which contains the reference safety information.

6.2 Documenting and Reporting of Adverse and Serious Adverse Events

The investigator is responsible for ensuring that all AEs and SAEs that are observed or reported during the study, as outlined in the prior sections, are recorded on the CRF. All SAEs also must be reported on the SAE form (see Section 6.2.4).

6.2.1 Adverse Event Reporting Period

After the signing of the ICF, all SAEs must be reported. After the first dose of study drug, all AEs, irrespective of seriousness, must be reported.

AE reporting, irrespective of seriousness, ends 30 days after the last dose of study drug.

SAEs considered related to study drug(s) or study procedures occurring after the end of the AE reporting period (as defined above) must be reported.
If an SAE is present at the last study visit, the SAE should be followed to resolution or until the investigator assesses the subject as stable, or the subject is lost to follow-up or withdraws consent. Resolution/stable means the subject has returned to baseline state of health or the investigator does not expect any further improvement or worsening of the event.

6.2.2 Assessment of Adverse Events

Investigators will assess the occurrence of AEs and SAEs at all subject evaluation timepoints during the study. All AEs and SAEs whether volunteered by the subject, discovered by study personnel during questioning, detected through physical examination, clinically significant laboratory test (e.g., requiring change in study drug dose or discontinuation of study drug or any other medical intervention), or other means will be recorded in the subject’s medical record and on the AE CRF and, when applicable, on an SAE form.

Disease progression itself is not considered an AE; however, signs and symptoms of disease progression may be recorded as AEs or SAEs.

Each recorded AE or SAE will be described by its duration (e.g., start and end dates), severity, regulatory seriousness criteria, if applicable, suspected relationship to the study drug (see following guidance), and any actions taken. The causality of AEs to the study drug will be assessed by means of the question: ‘Is there a reasonable possibility that the event may have been caused by the study drug?’ Answer Yes or No.

See Appendix 2 for more detail on assessing causality.

6.2.3 Pregnancy

The investigator should report all pregnancies in study subjects and in the partners of study subjects within 24 hours using the Pregnancy Report Form. This form should be faxed or emailed to Acerta Pharma Drug Safety. Any pregnancy-associated SAE must be reported using the SAE report form, according to the usual timelines and directions for SAE reporting (Section 6.2.4).

Any uncomplicated pregnancy that occurs in a study subject or a partner of a treated subject during this study will be reported for tracking purposes only, if agreed to by the subject or the partner of the subject in this study. All pregnancies and partner pregnancies that are identified during or after this study, wherein the estimated date of conception is determined to have occurred from the time of consent to 2 days after the
last dose of study medication will be reported, followed to conclusion, and the outcome reported, as long as the subject or partner has consented to participate in follow-up.

Pregnancy itself is not regarded as an AE unless there is suspicion that the investigational product under study may have interfered with the effectiveness of a contraceptive medication. Likewise, elective abortions without complications are not considered AEs. Any SAEs associated with pregnancy (e.g., congenital abnormalities/birth defects/spontaneous miscarriages or any other serious events) must additionally be reported as such using the SAE Form.

Subjects should be instructed to immediately notify the investigator of any pregnancies. Any woman receiving acalabrutinib who become pregnant must immediately discontinue study drug. The investigator should counsel the subject, discussing any risks of continuing the pregnancy and any possible effects on the fetus.

Upon completion of the pregnancy, additional information on the mother, pregnancy, and baby will be collected and sent to [INCOMPLETABLE].

6.2.4 Expedited Reporting Requirements for Serious Adverse Events and Adverse Events of Special Interest

All SAEs and AESIs must be reported within 24 hours of discovery. All initial SAE/AESI reports and follow-up information will be reported using the protocol-specific electronic data capture system. If electronic SAE/AESI reporting is not available, paper SAE/AESI forms must be emailed or faxed to Acerta Pharma Drug Safety, or designee. Acerta Pharma may request follow-up and other additional information from the investigator (e.g., hospital admission/discharge notes and laboratory results).

Whenever possible, SAEs/AEs should be reported by diagnosis term not as a constellation of symptoms. Death due to disease progression should be recorded on the appropriate form in the electronic data capture system. If the primary cause of death is disease progression, the death due to disease progression should not be reported as an SAE. If the primary cause of death is something other than disease progression, then the death should be reported as an SAE with the primary cause of death as the event term, as death is typically the outcome of the event, not the event itself. The primary cause of death on the autopsy report should be the term reported. Autopsy and postmortem reports must be forwarded to Acerta Pharma Drug Safety, or designee, as outlined above.
If study drug is discontinued because of an SAE, this information must be included in the SAE report.

An SAE may qualify for mandatory expedited reporting to regulatory authorities if the SAE is attributable to the investigational product (or if a causality assessment is not provided for the SAE, in which case a default of ‘related’ may be used for expedited reporting purposes) and the SAE is not listed in the current acalabrutinib Investigator Brochure (i.e., an unexpected event). In this case, Acerta Pharma Drug Safety/Designee will forward a formal notification describing the suspected unexpected serious adverse reaction (SUSAR) to all investigators. Each investigator must then notify his or her IRB/IEC of the SUSAR.

### Drug Safety Contact Information

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fax</td>
<td></td>
</tr>
<tr>
<td>Email</td>
<td></td>
</tr>
</tbody>
</table>

#### 6.2.5 Type and Duration of Follow-up of Subjects After Adverse Events

All AEs and SAEs that are encountered during the protocol-specified AE reporting period should be followed to resolution, or until the investigator assesses the event as stable, a new anticancer therapy is initiated, or the subject is lost to follow-up or withdraws consent.

#### 7.0 STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS

Acerta Pharma retains the right to terminate the study and remove all study materials from a study site at any time. Specific circumstances that may precipitate such termination include:

- Unsatisfactory subject enrollment with regard to quality or quantity
- Significant or numerous deviations from study protocol requirements, such as failure to perform required evaluations on subjects and maintain adequate study records
- Inaccurate, incomplete, or late data recording on a recurrent basis
- The incidence and/or severity of AEs in this or other studies indicating a potential health hazard caused by the study treatment
7.1 Regulatory and Ethical Compliance

This clinical study was designed and will be implemented in accordance with the protocol, the International Council on Harmonisation Harmonized Tripartite Guidelines for Good Clinical Practices, applicable local regulations (including US Code of Federal Regulations Title 21 and European Directive 2001/20/EC), and the ethical principles laid down in the Declaration of Helsinki.

7.2 Institutional Review Board and Independent Ethics Committee

The investigator will submit this protocol, the ICF, Investigator Brochure, and any other relevant supporting information (e.g., all advertising materials) to the appropriate IRB/IEC for review and approval before study initiation. A signed protocol approval page; a letter confirming IRB/IEC approval of the protocol and informed consent; and a statement that the IRB/IEC is organized and operates according to Good Clinical Practices and the applicable laws and regulations; must be forwarded to Acerta Pharma before screening subjects for the study. Additionally, sites must forward a signed Food and Drug Administration (FDA) 1572 form (Statement of Investigator) to Acerta Pharma before screening subjects for study enrollment. Amendments to the protocol must also be approved by the IRB/IEC and local regulatory agencies, as appropriate, before the implementation of changes in this study.

7.3 Informed Consent and Protected Subject Health Information Authorization

A copy of the IRB/IEC-approved ICF must be forwarded to Acerta Pharma for regulatory purposes. The investigator, or designee (designee must be listed on the Study Personnel Responsibility/Signature Log, see Section 7.12), must explain to each subject the purpose and nature of the study, the study procedures, the possible adverse effects, and all other elements of consent as defined in § 21 Code of Federal Regulations Part 50 and other applicable national and local regulations governing informed consent. Each subject must provide a signed and dated ICF before enrollment into this study. If allowed by the protocol, a legal representative may sign the ICF for a subject incapable of giving consent. Signed consent forms must remain in each subject’s study file and be available for verification by study monitors at any time.

In accordance with individual local and national patient privacy regulations, the investigator or designee must explain to each subject that for the evaluation of study results, the subject’s protected health information obtained during the study may be
shared with Acerta Pharma and its designees, regulatory agencies, and IRBs/IECs. As the study Sponsor, Acerta Pharma will not use the subject’s protected health information or disclose it to a third party without applicable subject authorization. It is the investigator’s or designee’s responsibility to obtain written permission to use protected health information from each subject, or if appropriate, the subject’s legal guardian. If a subject or subject’s legal guardian withdraws permission to use protected health information, it is the investigator’s responsibility to obtain the withdrawal request in writing from the subject or subject’s legal guardian and to ensure that no further data will be collected from the subject. Any data collected on the subject before withdrawal will be used in the analysis of study results.

7.4 Subject Screening Log
The investigator must keep a record that lists all subjects considered for enrollment (including those who did not undergo screening) in the study. For those subjects subsequently excluded from enrollment, record the reason(s) for exclusion.

7.5 Case Report Forms
Authorized study site personnel (see Section 7.12) will complete CRFs designed for this study according to the completion guidelines that will be provided. The investigator will ensure that the CRFs are accurate, complete, legible, and completed promptly. For record retention policies, refer to Section 7.8.

7.6 Study Monitoring Requirements
Representatives of Acerta Pharma or its designee will monitor this study until completion. Monitoring will be conducted through personal visits with the investigator and site staff as well as any appropriate communications by mail, fax, email, or telephone. The purpose of monitoring is to ensure compliance with the protocol and the quality and integrity of the data. This study is also subject to reviews or audits by the sponsor, regulatory authorities, or ethics committees.

Every effort will be made to maintain the anonymity and confidentiality of all subjects during this clinical study. However, because of the experimental nature of this treatment, the investigator agrees to allow the IRB/IEC, representatives of Acerta Pharma, its designated agents, and authorized employees of the appropriate regulatory agencies to inspect the facilities used in this study and, for purposes of verification, allow direct access to the hospital or clinic records of all subjects enrolled into this study. This includes providing by fax, email, or regular mail de-identified copies of radiology,
pathology, and/or laboratory results when requested by the sponsor. A statement to this effect will be included in the informed consent and permission form authorizing the use of protected health information.

7.7 **Investigational Study Drug Accountability**

Acalabrutinib capsules must be kept in a locked limited-access cabinet or space. The study drug must not be used outside the context of this protocol.

Study drug accountability records must be maintained and readily available for inspection by representatives of Acerta Pharma or regulatory authorities at any time.

Each shipment of study drug will contain a Clinical Supplies Shipping Receipt Form (CSSF). If it is used, the Drug Re-Order Form (provided in the pharmacy binder) must also be included in the site’s drug accountability records.

Contents of each shipment must be visually inspected to verify the quantity and to document the condition of study drug capsules. Following receipt of study drug, the designated recipient completes and signs the CSSF. A copy of the signed and dated CSSF must be faxed or emailed to Acerta Pharma at the fax number/email address listed on the form; this completed form should be filed in the pharmacy binder.

An Investigational Drug Accountability Log must be used for drug accountability. For accurate accountability, the following information must be noted when drug supplies are used during the study:

1. study identification number (ACE-WM-001)
2. subject identification number
3. lot number(s) of acalabrutinib dispensed for that subject
4. date and quantity of drug dispensed
5. any unused drug returned by the subject

At study initiation, the monitor will evaluate and approve the site’s procedure for investigational product disposal/destruction to ensure that it complies with Acerta Pharma’s requirements. If the site cannot meet Acerta Pharma’s requirements for disposal/destruction, arrangements will be made between the site and Acerta Pharma or its representative, for return of unused investigational product. Before disposal/destruction, final drug accountability and reconciliation must be performed by the monitor.
All study supplies and associated documentation will be regularly reviewed and verified by the monitor.

7.8 Record Retention

The investigator and other appropriate study staff are responsible for maintaining all documentation relevant to the study. Mandatory documentation includes copies of study protocols and amendments, each FDA Form 1572, IRB/IEC approval letters, signed ICFs, drug accountability records, SAE forms transmitted to Acerta Pharma, subject files (source documentation) that substantiate entries in CRFs, and all relevant correspondence and other documents pertaining to the conduct of the study.

An investigator shall retain records for a period of at least 2 years after the date the last marketing application is approved for the drug for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and regulatory authorities have been notified. The investigator must notify Acerta Pharma and obtain written approval from Acerta Pharma before destroying any clinical study records at any time. Acerta Pharma will inform the investigator of the date that study records may be destroyed or returned to Acerta Pharma.

Acerta Pharma must be notified in advance of, and Acerta Pharma must provide express written approval of, any change in the maintenance of the foregoing documents if the investigator wishes to move study records to another location or assign responsibility for record retention to another party. If the investigator cannot guarantee the archiving requirements set forth herein at his or her study site for all such documents, special arrangements must be made between the investigator and Acerta Pharma to store such documents in sealed containers away from the study site so that they can be returned sealed to the investigator for audit purposes.

7.9 Protocol Amendments

Acerta Pharma will initiate any change to the protocol in a protocol amendment document. The amendment will be submitted to the IRB/IEC together with, if applicable, a revised model ICF. If the change in any way increases the risk to the subject or changes the scope of the study, then written documentation of IRB/IEC approval must be received by Acerta Pharma before the amendment may take effect. Additionally under this circumstance, information on the increased risk and/or change in scope must
be provided to subjects already actively participating in the study, and they must read, understand, and sign any revised ICF confirming willingness to remain in the study.

7.10 Publication of Study Results

Authorship, in general, will follow the recommendations of the International Committee of Medical Journal Editors (International Committee of Medical Journal Editors 2014).

7.11 Clinical Study Insurance

Clinical study insurance has been obtained according to the laws of the countries where the study will be conducted. An insurance certificate will be made available to the participating sites at the time of study initiation.

7.12 General Investigator Responsibilities

The principal investigator must ensure that:

1. He or she will personally conduct or supervise the study.
2. His or her staff and all persons who assist in the conduct of the study clearly understand their responsibilities and have their names included in the Study Personnel Responsibility/Signature Log.
3. The study is conducted according to the protocol and all applicable regulations.
4. The protection of each subject’s rights and welfare is maintained.
5. Signed and dated informed consent and, when applicable, permission to use protected health information are obtained from each subject before conducting nonstandard of care study procedures. If a subject or subject’s legal guardian withdraws permission to use protected health information, the investigator will obtain a written request from the subject or subject’s legal guardian and will ensure that no further data be collected from the subject.
6. The consent process is conducted in compliance with all applicable regulations and privacy acts.
7. The IRB/IEC complies with applicable regulations and conducts initial and ongoing reviews and approvals of the study.
8. Any amendment to the protocol is submitted promptly to the IRB/IEC.
9. Any significant protocol deviations are reported to Acerta Pharma and the IRB/IEC according to the guidelines at each study site.
10. CRF pages are completed promptly.
11. All Investigational New Drug Safety Reports and SUSAR Reports are submitted promptly to the IRB/IEC.
12. All SAEs are reported to Acerta Pharma Drug Safety/Designee within 24 hours of knowledge and to the IRB/IEC per their requirements.
8.0 REFERENCES


IMBRUVICA [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2014.


Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA). Front Biosci 2000;5:D917-D928.
9.0 APPENDICES

Appendix 1. Performance Status Scores

<table>
<thead>
<tr>
<th>Grade</th>
<th>ECOG</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Fully active, able to carry on all pre-disease performance without restriction</td>
</tr>
<tr>
<td>1</td>
<td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours</td>
</tr>
<tr>
<td>3</td>
<td>Capable of only limited self-care, confined to bed or chair more than 50% of waking hours</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair</td>
</tr>
<tr>
<td>5</td>
<td>Dead</td>
</tr>
</tbody>
</table>

As published in Am J Clin Oncol:


Credit: Eastern Cooperative Oncology Group Chair: Robert Comis, MD
Appendix 2. Adverse Event Assessment of Causality

Is there a reasonable possibility that the event may have been caused by study drug?
No___ Yes___

The descriptions provided below will help guide the principal investigator in making the decision to choose either “yes” or “no”:

No = There is no reasonable possibility that the event may have been caused by study drug.

The adverse event:

- May be judged to be due to extraneous causes such as disease or environment or toxic factors
- May be judged to be due to the subject’s clinical state or other therapy being administered
- Is not biologically plausible
- Does not reappear or worsen when study drug is re-administered
- Does not follow a temporal sequence from administration of study drug

Yes = There is a reasonable possibility that the event may have been caused by study drug.

The adverse event:

- Follows a temporal sequence from administration of study drug
- Is a known response to the study drug based on clinical or preclinical data
- Could not be explained by the known characteristics of the subject's clinical state, environmental or toxic factors, or other therapy administered to the subject
- Disappears or decreases upon cessation or reduction of dose of study drug
- Reappears or worsens when study drug is re-administered
Appendix 3. Known Strong In Vivo Inhibitors and Inducers of CYP3A

<table>
<thead>
<tr>
<th>Strong Inhibitors of CYP3A&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Strong Inducers of CYP3A&lt;sup&gt;e&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>boceprevir</td>
<td>carbamazepine&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td>clarithromycin&lt;sup&gt;b&lt;/sup&gt;</td>
<td>phenytoin&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td>conivaptin&lt;sup&gt;b&lt;/sup&gt;</td>
<td>rifampin&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td>grapefruit juice&lt;sup&gt;c&lt;/sup&gt;</td>
<td>St John's wort&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td>indinavir</td>
<td></td>
</tr>
<tr>
<td>itraconazole&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>ketoconazole&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>lopinavir/ritonavir&lt;sup&gt;b&lt;/sup&gt; (combination drug)</td>
<td></td>
</tr>
<tr>
<td>mibefradil&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>nefazodone</td>
<td></td>
</tr>
<tr>
<td>nelfinavir</td>
<td></td>
</tr>
<tr>
<td>posaconazole</td>
<td></td>
</tr>
<tr>
<td>ritonavir&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>saquinavir</td>
<td></td>
</tr>
<tr>
<td>telaprevir</td>
<td></td>
</tr>
<tr>
<td>telithromycin</td>
<td></td>
</tr>
<tr>
<td>voriconazole</td>
<td></td>
</tr>
</tbody>
</table>

- A strong inhibitor for CYP3A is defined as an inhibitor that increases the AUC of a substrate for CYP3A by ≥ 5-fold.
- In vivo inhibitor of P-glycoprotein.
- The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-dependent. Studies have shown that it can be classified as a "strong CYP3A inhibitor" when a certain preparation was used (e.g., high dose, double strength) or as a "moderate CYP3A inhibitor" when another preparation was used (e.g., low dose, single strength).
- Withdrawn from the United States market because of safety reasons.
- A strong inducer for CYP3A is defined as an inducer that results in ≥ 80% decrease in the AUC of a substrate for CYP3A.
- In vivo inducer of P-glycoprotein.

Note: The list of drugs in these tables is not exhaustive. Any questions about drugs not on this list should be addressed to the medical monitor of the protocol.

Source:
## Appendix 4. Schedule of Assessments

<table>
<thead>
<tr>
<th>Screening&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Cycle 1 Days (± 2)</th>
<th>Cycle 2 Days (± 2)</th>
<th>Cycle 3 Days (± 2)</th>
<th>Cycles 4 and 5 Days (± 2)</th>
<th>Cycles 6-12 Days (± 2)</th>
<th>Cycles 15, 18, 21, 24 Days (± 2)</th>
<th>Cycles 27-48 Days (± 2)</th>
<th>Cycles 48+ Days (± 2)</th>
<th>TT Visit&lt;sup&gt;c&lt;/sup&gt;</th>
<th>SFU Visit&lt;sup&gt;c&lt;/sup&gt;</th>
<th>DFU&lt;sup&gt;d&lt;/sup&gt;</th>
<th>LTFU&lt;sup&gt;e&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm eligibility</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE/Vital signs&lt;sup&gt;g&lt;/sup&gt;/Weight&lt;sup&gt;f&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>ECOG status&lt;sup&gt;h&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>ECG&lt;sup&gt;i&lt;/sup&gt;</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory assessments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine or serum pregnancy test&lt;sup&gt;j&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Hematology&lt;sup&gt;k&lt;/sup&gt;</td>
<td>x</td>
<td>x&lt;sup&gt;m&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Serum chemistry&lt;sup&gt;l&lt;/sup&gt;</td>
<td>x</td>
<td>x&lt;sup&gt;m&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Urinalysis&lt;sup&gt;n&lt;/sup&gt;</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T/B/NK cell count&lt;sup)o&lt;/sup&gt;</td>
<td>x&lt;sup&gt;m&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>C6 and C12 only</td>
<td>C18 &amp; C24 only</td>
<td>Q6C starting at C27</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Ig &amp; M protein&lt;sup&gt;p&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x (Q6C)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>HBV PCR&lt;sup&gt;r&lt;/sup&gt;</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>QM</td>
<td>QM</td>
<td>QM</td>
<td>x</td>
<td>(Q3M)</td>
<td>Q3M</td>
<td>Q3M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow (aspirate and biopsy)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C12 only and to confirm CR</td>
<td>Only to confirm CR</td>
<td>Only to confirm CR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Screening: Days 0-3 (± 2)

<sup>b</sup> Cycle 48+ visits are open label visits for patients who have completed Cycle 48.

<sup>c</sup> TT, SFU, DFU, and LTFU visits are scheduled at the investigator’s discretion.

<sup>d</sup> DFU visits are open label visits for patients who have completed Cycle 48.

<sup>e</sup> LTFU visits are open label visits for patients who have completed Cycle 48.

<sup>f</sup> Vital signs: Blood pressure, heart rate, respiration, temperature.

<sup>g</sup> Physical examination.

<sup>h</sup> ECOG performance status.

<sup>i</sup> ECG: Electrocardiogram.

<sup>j</sup> Urine or serum pregnancy test.

<sup>k</sup> Hematology: Hemoglobin, hematocrit, platelets, white blood cell count.

<sup>l</sup> Serum chemistry: Glucose, lipids, liver enzymes, bicarbonate, calcium, bilirubin.

<sup>m</sup> Urinalysis: Complete urine analysis.

<sup>n</sup> T/B/NK cell count: Total white blood cell count, absolute neutrophil count, absolute lymphocyte count.

<sup>o</sup> Serum Ig & M protein: Immunoglobulin G and M protein.

<sup>p</sup> HBV PCR: Hepatitis B virus PCR.

<sup>q</sup> Bone marrow (aspirate and biopsy): Bone marrow aspiration and biopsy.

<sup>r</sup> CR: Complete response.
<table>
<thead>
<tr>
<th>Screening(^a)</th>
<th>Cycle 1</th>
<th>Cycle 2</th>
<th>Cycle 3</th>
<th>Cycles 4 and 5</th>
<th>Cycles 6-12</th>
<th>Cycles 15, 18, 21, 24</th>
<th>Cycles 27-48</th>
<th>Cycles 48+(^b)</th>
<th>TT Visit(^c)</th>
<th>SFU Visit(^c)</th>
<th>DFU(^d)</th>
<th>LTFU(^e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days (± 2)</td>
<td>1</td>
<td>8</td>
<td>15</td>
<td>22</td>
<td>28</td>
<td>15</td>
<td>28</td>
<td>28</td>
<td>28</td>
<td>28</td>
<td>28</td>
<td>28</td>
</tr>
<tr>
<td>Days (± 2)</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days (± 2)</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days (± 2)</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days (± 2)</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days (± 2)</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiologic assessment (as applicable) for extramedullary sites(^f)</td>
<td>(x)</td>
<td></td>
<td></td>
<td></td>
<td>C4 only</td>
<td>Q3C and to confirm CR</td>
<td>Q3C and to confirm CR</td>
<td>Q6C and to confirm CR</td>
<td>Q6C and to confirm CR</td>
<td>(x)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacodynamics/Molecular Testing</td>
<td>(x^a)</td>
<td>(x^b)</td>
<td>(x^c)</td>
<td>(x^d)</td>
<td>(x^e)</td>
<td>(x^f)</td>
<td>(x^g)</td>
<td>(x^h)</td>
<td>(x^i)</td>
<td>(x^j)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics(^u)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acalabrutinib dispensed</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(Q6C)</td>
<td></td>
</tr>
<tr>
<td>Study drug compliance</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(Q6C)</td>
<td></td>
</tr>
<tr>
<td>Response assessment(^t)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(Q6C)</td>
<td></td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(Q6C)</td>
<td></td>
</tr>
<tr>
<td>Adverse events(^v)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td></td>
</tr>
<tr>
<td>PRO(^w)</td>
<td>(x)</td>
<td></td>
<td></td>
<td>C4 only</td>
<td>C6, C9 &amp; C12 only</td>
<td>(x)</td>
<td>(x)</td>
<td>(x)</td>
<td>(Q6C)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival Status</td>
<td>(x)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AE=adverse event; C=cycle; CR=complete remission; DFU=discontinuation follow-up; ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; ET=early termination; Ig=immunoglobulin; LTFU=long-term follow-up; PCR=polymerase chain reaction; PE=physical examination; PRO=patient-reported outcomes; Q3C=every 3 cycles; Q3M=every 3 months; Q6C=every 6 cycles; Q6M=every 6 months; QM=every month; SAE=serious adverse event; SFU=safety follow-up; TT=treatment termination.

Footnotes for ACE-WM-001 Schedule of Assessments:

a. Screening tests should be performed within 21 days before the first administration of study drug, unless otherwise indicated.
b. The end of study is defined as the last subject’s last visit. Subjects who are deriving clinical benefit from acalabrutinib may continue on study until a rollover protocol is available.
c. A TT visit is required for subjects who permanently discontinue study drug early for any reason, including disease progression. A 30-day (+7 days) SFU visit after the last dose of study drug is required when subjects discontinue study drug. The TT visit should be scheduled within 7 days of the last dose of study drug, if possible, and is not required for subjects who discontinue from study treatment within 10 days after a scheduled study visit. Each subject should be followed until the SFU visit at 30 (+7) days after his or her last dose of study drug to monitor for resolution or progression of AEs and to document the occurrence of any new events, regardless of whether the subject receives a new anticancer therapy or demonstrates disease progression within this timeframe.
d. Subjects who discontinue for reasons other than progressive disease (including subjects who discontinued due to AE and start use of alternative anticancer therapy) will be followed approximately Q3M until progressive disease. During this period, for subjects who require scans, scans will be done Q3M until 2 years, and then Q6M thereafter until progression. Additionally, serum IgM and physical examination will be collected.

e. Once subjects progress—for all subjects who have not withdrawn consent—they will be contacted approximately Q3M by clinic visit or telephone, to assess survival and the use of alternative anticancer therapy until death or loss to follow-up.

f. The screening physical examination will include, at a minimum, the general appearance of the subject, height (screening only) and weight, and examination of the skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system. Symptom-directed physical examinations, including extramedullary disease assessments by palpation, will be done thereafter. Assessments will be made Q3C through Cycle 48, then Q6C thereafter.

g. Vital signs (blood pressure, heart rate, respiratory rate, and temperature) will be assessed after the subject has rested in the sitting position. Assessments will be made Q3C through Cycle 48, then Q6C thereafter.

h. ECOG assessments will be made Q3C through Cycle 48, then Q6C thereafter.

i. Subjects should be in supine position and resting for ≥10 minutes before study-related ECGs.

j. Women of childbearing potential only. Testing will be done locally by use of central laboratory provided kits. Pregnancy testing may be done by local laboratories and can be done more frequently than the protocol-defined schedule, if required by local regulatory authorities. In general, assessments will be made Q3C through Cycle 48, then Q6C thereafter.

k. Hematology will include complete blood count with differential and platelet and reticulocyte counts. Cycle 1 Day 1 hematology does not need to be repeated if screening hematology was within 5 days. Assessments will be made Q3C through Cycle 48, then Q6C thereafter.

l. Serum chemistry will include albumin, alkaline phosphatase, bone-specific alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bicarbonate, blood urea nitrogen, calcium, chloride, creatinine, c-terminal telopeptide, glucose, lactate dehydrogenase, magnesium, phosphate, potassium, sodium, total bilirubin, total protein, and uric acid. Cycle 1 Day 1 serum chemistry does not need to be repeated if screening chemistry was within 5 days. Assessments will be made Q3C through Cycle 48, then Q6C thereafter.

m. The indicated samples at this timepoint (Cycle 1 Day 1) must be drawn predose.

n. Urinalysis will include pH, ketones, specific gravity, bilirubin, protein, blood, and glucose.

o. T/B/NK cell count (i.e., CD3+, CD4+, CD8+, CD19+, CD16/56+). During Cycle 6 through Cycle 24, assessments will only be done at the end of Cycle 6, 12, 18, and 24. During Cycle 24 through Cycle 48, assessments will be done Q6C starting at Cycle 27. Assessments after Cycle 48 are not required.

p. Serum immunoglobulin will include IgG, IgM, IgA and Serum M protein. Starting at Cycle 6, IgG, IgM, IgA, and serum M protein will be done Q3C (12 weeks, ±7 days) through Cycle 48, then Q6C thereafter.

q. Subjects who are hepatitis B core antibody positive (or have a known history of HBV infection) should be monitored monthly with a quantitative PCR test for HBV DNA. Assessments will be made QM from Cycle 6 to Cycle 48 or early discontinuation, and then Q3M thereafter. Any subject with a rising viral load (above lower limit of detection) should discontinue study drug and have antiviral therapy instituted and a consultation with a physician with expertise in managing hepatitis B.

r. Pretreatment extramedullary disease assessment including CT scan should be performed within 30 days before the first dose. A CT scan with contrast (unless contraindicated) of the chest, abdomen, and pelvis and any other disease sites (e.g., neck) are required for the pretreatment assessment. For subjects with baseline (screening) extramedullary disease, follow-up radiologic assessments are required at the end of Cycle 2 (±7 days), Cycle 4 (±7 days), Cycle 6 (±7 days), then every 3 cycles (12 weeks, ±7 days) until Cycle 27, then every 6 cycles thereafter or more frequently at the investigator’s discretion. At all other visits, extramedullary disease assessments will be done by physical examination and laboratory results. A bone marrow aspirate and biopsy will be done at screening or up to 60 days before the first dose of study drug. Bone marrow aspirate and biopsy are also required at end of Cycle 2 and Cycle 12, which must be done within 4 weeks of the contemporaneous radiologic evaluation. Furthermore, bone marrow and radiologic (as applicable) assessments are required for confirmation of complete remission. Pathologic review of the bone marrow aspirate and biopsy will be performed by a central laboratory or local laboratory, if central laboratory is unavailable for confirmation of WM diagnosis. When possible, extra bone marrow tissue may be used for PD evaluation.

s. PD samples will be drawn predose and 4 hours (±10 minutes) postdose on the days indicated. This sampling will be limited to a subset of subjects as described in the protocol and timepoints are relative to the morning dose. Molecular testing may be performed using the blood samples collected for PD testing (when available). Molecular testing will include, but may not be limited to, immunoglobulin heavy-chain variable mutational status, CXCR4S338X, and MYD88 L265P.

r. PD samples will be drawn predose on the days indicated. This sampling will be limited to a subset of subjects as described in the protocol and timepoints are relative to the morning dose. A PD sample will also be collected at disease progression (preferably at the TT visit). Molecular testing may be performed using the
blood samples collected for PD testing (when available). Molecular testing will include, but may not be limited to, immunoglobulin heavy-chain variable mutational status, CXCR4<sup>S338X</sup>, and MYD88 L265P.

u. PK samples will be drawn per Table 2. This sampling will be limited to a subset of subjects as described in the protocol and timepoints are relative to the morning dose.

v. After the end of the protocol-defined AE reporting period (see Section 6.2.1), only SAEs considered related to study drug(s) or study procedures are required to be collected.

w. PRO assessment will be done at screening, at the end of Cycle 2, Cycle 4, and Cycle 6; and then Q6C thereafter until documentation of progressive disease or use of alternative anticancer therapy.
Appendix 5. Actions Required in Cases of Increases in Liver Biochemistry and Evaluation of Hy’s Law

INTRODUCTION

This appendix describes the process to be followed to identify and appropriately report potential Hy’s law (PHL) cases and Hy’s law (HL) cases. It is not intended to be a comprehensive guide to the management of elevated liver biochemistries.

During the course of the study, the investigator will remain vigilant for increases in liver biochemistry. The investigator is responsible for determining whether a subject meets PHL criteria at any point during the study. All sources of laboratory data are appropriate for the determination of PHL and HL events; this includes samples taken at scheduled study visits and other visits, including central and all local laboratory evaluations, even if collected outside of the study visits (e.g., PHL criteria could be met by an elevated ALT from a central laboratory and/or elevated total bilirubin from a local laboratory). The investigator will also review adverse event (AE) data (e.g., for AEs that may indicate elevations in liver biochemistry) for possible PHL events.

The investigator participates with the sponsor in the review and assessment of cases meeting PHL criteria to agree whether HL criteria are met. HL criteria are met if there is no alternative explanation for the elevations in liver biochemistry other than drug-induced liver injury (DILI) caused by the investigational medicinal product (IMP). The investigator is responsible for recording data pertaining to PHL/HL cases and for reporting AEs and serious adverse events (SAEs) according to the outcome of the review and assessment in line with standard safety-reporting processes.

DEFINITIONS

Potential Hy’s Law

AST or ALT $\geq 3 \times \text{ULN}$ together with total bilirubin $\geq 2 \times \text{ULN}$ at any point during the study after the start of study drug, irrespective of an increase in alkaline phosphatase.

Hy’s Law

AST or ALT $\geq 3 \times \text{ULN}$ together with total bilirubin $\geq 2 \times \text{ULN}$, where no reason other than the IMP can be found to explain the combination of increases (e.g., elevated alkaline phosphatase indicating cholestasis, viral hepatitis, or another drug).
For PHL and HL, the elevation in transaminases must precede or be coincident with (i.e., on the same day) the elevation in total bilirubin, but there is no specified timeframe within which the elevations in transaminases and total bilirubin must occur.

**IDENTIFICATION OF POTENTIAL HY’S LAW CASES**

Laboratory data must be comprehensively reviewed by the investigator for each subject to identify laboratory values meeting the following criteria:

- ALT ≥3 x ULN
- AST ≥3 x ULN
- Total bilirubin ≥2 x ULN

When the identification criteria are met from central or local laboratory results, the investigator will perform the following:

- Notify the sponsor representative/medical monitor by telephone and report the case as an SAE of Potential Hy’s law; seriousness criteria “Important medical event” and causality assessment “yes/related” or in accordance with the clinical study protocol as appropriate.
- Request a repeat of the test (new blood draw) without delay
- Complete the appropriate unscheduled laboratory electronic Case Report Form (eCRF) module(s)
- Perform follow-up on subsequent laboratory results according to the guidance provided in the clinical study protocol, as applicable

**REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW CASES**

The instructions in this section should be followed by the investigator for all cases where PHL criteria are met.

As soon as possible after the biochemistry abnormality is initially detected, the study medical monitor and the investigator will review available data, to agree whether there is an alternative explanation for meeting PHL criteria other than DILI caused by the IMP and to ensure that timely analysis and reporting to health authorities within 15 calendar days from the date PHL criteria were met.

Where there is an agreed alternative explanation for the ALT or AST and total bilirubin elevations, a determination of whether the alternative explanation is an AE will be made and, subsequently, whether the AE meets the criteria for an SAE:

- If the alternative explanation is not an AE, record the alternative explanation on the appropriate eCRF.
• If the alternative explanation is an AE/SAE, update the previously submitted PHL SAE accordingly with the new information (reassessing event term, causality, and seriousness criteria) following the sponsor’s standard processes.

If it is agreed that there is no explanation that would explain the ALT or AST and total bilirubin elevations other than the IMP, then:

• Send updated SAE (report term “Hy’s law”) according to the sponsor’s standard processes:
  o The “Medically Important” serious criterion should be used if no other serious criteria apply.
  o Because there is no alternative explanation for the HL case, a causality assessment of “related” should be assigned.

If there is an unavoidable delay of over 15 calendar days in obtaining the information necessary to assess whether the case meets the criteria for HL, then it is assumed that there is no alternative explanation until an informed decision can be made:

• Provide any further update to the previously submitted SAE of PHL (report term now “Hy’s law case”), ensuring causality assessment is related to IMP and seriousness criteria are medically important, according to clinical study protocol process.

• Continue follow-up and review according to the agreed plan. After the necessary supplementary information is obtained, repeat the review and assessment to determine whether HL criteria are still met. Update the previously submitted PHL SAE report following the clinical study protocol process, according to the outcome of the review.

**ACTIONS REQUIRED FOR REPEAT EPISODES OF POTENTIAL HY’S LAW**

This section is applicable when a subject meets PHL criteria while receiving study treatment and has already met PHL criteria at a previous on-study treatment visit. The requirement to conduct follow-up, review, and assessment of a repeat occurrence(s) of PHL is based on the nature of the alternative cause identified for the previous occurrence.

The investigator should determine the cause for the previous occurrence of PHL and answer the following question:

Was the alternative cause for the previous occurrence of PHL determined to be the disease under study (e.g., chronic or progressing malignant disease, severe infection, or liver disease)?

• **If the answer is No:**
  Follow the process described in “Potential Hy’s Law Criteria Met” in this appendix for reporting PHL as an SAE.

• **If the answer is Yes:**
  Determine whether there has been a significant change in the subject’s condition compared with the previous occurrence of PHL. Note: A “significant” change in the subject’s condition refers to a clinically relevant change in any of the individual
liver biochemistry parameters (ALT, AST, or total bilirubin) in isolation or in combination or a clinically relevant change in associated symptoms. The determination of whether there has been a significant change will be at the discretion of the investigator; this may be in consultation with the study medical monitor if there is any uncertainty.

- If there is no significant change, no action is required.
- If there is a significant change, follow the process described in “Potential Hy’s Law Criteria Met” in this appendix for reporting PHL as an SAE.

LABORATORY TESTS

The list below represents a comprehensive list of follow-up tests that may aid in assessing PHL/HL.

Test results used to assess PHL/HL should be recorded on the appropriate eCRF.

<table>
<thead>
<tr>
<th>Additional standard chemistry and coagulation tests</th>
<th>GGT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LDH</td>
</tr>
<tr>
<td></td>
<td>Prothrombin time</td>
</tr>
<tr>
<td></td>
<td>INR</td>
</tr>
<tr>
<td>Viral hepatitis</td>
<td>IgM anti-HAV</td>
</tr>
<tr>
<td></td>
<td>IgM and IgG anti-HBc</td>
</tr>
<tr>
<td></td>
<td>HBsAg</td>
</tr>
<tr>
<td></td>
<td>HBV DNA</td>
</tr>
<tr>
<td></td>
<td>IgM and IgG anti-HCV</td>
</tr>
<tr>
<td></td>
<td>HCV RNA</td>
</tr>
<tr>
<td></td>
<td>IgM anti-HEV</td>
</tr>
<tr>
<td></td>
<td>HEV RNA</td>
</tr>
<tr>
<td>Other viral infections</td>
<td>IgM &amp; IgG anti-CMV</td>
</tr>
<tr>
<td></td>
<td>IgM &amp; IgG anti-HSV</td>
</tr>
<tr>
<td></td>
<td>IgM &amp; IgG anti-EBV</td>
</tr>
<tr>
<td>Alcoholic hepatitis</td>
<td>Carbohydrate deficient transferrin (CD-transferrin)</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td>Antinuclear antibody</td>
</tr>
<tr>
<td></td>
<td>Anti-Liver/Kidney Microsomal Ab (Anti-LKM)</td>
</tr>
<tr>
<td></td>
<td>Anti-Smooth Muscle Ab (ASMA)</td>
</tr>
<tr>
<td>Metabolic diseases</td>
<td>alpha-1-antitrypsin</td>
</tr>
<tr>
<td></td>
<td>Ceruloplasmin</td>
</tr>
<tr>
<td></td>
<td>Iron</td>
</tr>
<tr>
<td></td>
<td>Ferritin</td>
</tr>
<tr>
<td></td>
<td>Transferrin</td>
</tr>
<tr>
<td></td>
<td>Transferrin saturation</td>
</tr>
</tbody>
</table>

Reference